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1 RÉSUMÉ 
Il a déjà été démontré que les statines (ou inhibiteurs de la HMG-CoA réductase) sont efficaces 
pour réduire le LDL-cholestérol et elles se sont depuis établies comme étant le pilier dans le 
traitement de la dyslipidémie. Toutefois,  environ 10 pourcent des utilisateurs de statines 
souffrent d'effets indésirables, généralement sous forme de myopathie qui est souvent 
accompagnée d’un taux élevé de la créatine kinase (CK) plasmatique. Il est fréquent que les 
patients doivent arrêter les statines à cause d’un taux de CK dépassant un seuil de référence. 
Nous avons examiné le taux de CK de près de  6000 participants de la biobanque de l’ICM, qui 
ont récemment été génotypés à l'aide de la micropuce d'ADN ExomChip d'Illumina. Des études 
antérieures ont démontré une association significative entre le taux de CK plasmatique et des 
polymorphismes génétiques et nous avons cherché à répliquer ces résultats par association 
génétique et à l'aide du test SKAT pour les polymorphismes rares. Nous avons répliqué les 
résultats dans le gène CKM (rs11559024, p=1.59x10
-23
) et le gène LILRB5 (rs12975366, 
p=1.44x10
-26
) dans le chromosome 19. Nous espérons que ces résultats seront éventuellement 
utilisés en clinique pour la prédiction des taux de référence de CK personnalisés selon le profil 
génétique des patients utilisateurs de statines. 
Mots-clés: statine, créatine kinase, myopathie 
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2 ABSTRACT 
Statins (HMG-CoA reductase inhibitors) have been shown to reduce LDL-cholesterol and are 
undoubtedly the mainstay in the treatment of hyperlipidemia. Approximately 10 percent of statin 
users suffer from adverse side effects, the most common being muscle myopathy. Muscle 
myopathy is often accompanied by elevated levels of plasma creatine kinase (CK). Oftentimes, 
patients are taken off statins after their CK levels surpass a reference threshold. We looked at CK 
levels in the MHI Biobank, which have recently been genotyped in over 6000 participants with 
the Illumina ExomChip. Prior studies have found significant association between plasma CK 
levels and genetic variants and we aimed to replicate these findings using a genome wide 
association and a SKAT burden test for rare variants. We were able to replicate findings in the 
CKM gene (rs11559024, p=1.59x10
-23
) and LILRB5 gene (rs12975366, p=1.44x10
-23
) in 
chromosome 19. We hope that these results will eventually be utilized in clinical statin care by 
aiding in the prediction of personalized reference CK levels based on genetic information for 
patients using statins.   
Key words: statin, creatine kinase, myopathy 
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7 INTRODUCTION 
7.1 Background on statins 
Statins (HMG-CoA (hydroxy-methylglutaryl-coenzyme A) reductase inhibitors) have been 
shown to reduce LDL-cholesterol and are undoubtedly the mainstay in the treatment of 
hyperlipidemia. Statins have revolutionized primary and secondary prevention of coronary 
atherosclerotic disease due to their lipid-lowering properties and other pleiotropic effects that 
affect atherosclerotic plaque stability
2
. Statins work as an inhibitor as they share an HMG-CoA 
like moiety that acts as a HMG-CoA reductase by competing with the HMG-CoA at the binding 
site. 
 
 Among persons with coronary artery disease, there is an evident decrease in mortality in 
statin users which persists in all age groups. One study found that when non-statin users were 
compared to statin users, mortality decreased from 29.5% to 8.5% in participants greater than or 
equal to 80 years of age, 18.7% to 6.9% in participants 65 to 79 years old and 8.9% to 3.1% in 
participants younger than 65
3
. The efficacy of statins as primary prevention on patients with high 
cholesterol but no history of heart disease is unclear; one meta-analysis found no significant 
mortality benefits
4
. When used in secondary prevention, statins have been found to decrease 
cardiovascular endpoints in patients with pre-existing cardiovascular disease and lower LDL-
cholesterol by an average of 1.8 mmol (70 mg/dl), preventing approximately 60% of cardiac 
events
5
. 
  
The synthesis of a cholesterol lowering drug began in 1971 with Akira Endo, a Japanese 
biochemist. She speculated that fungi such as molds and mushrooms would produce antibiotics 
2 
 
that inhibited HMG-CoA reductase. Endo’s team identified mevastatin, a molecule produced by 
the fungus Penicillium citrinum. Although mevastatin is thought to be the first known statin, it 
was never deemed safe for human use
6
 as adverse effects included tumors, muscle deterioration 
and death. In 1982, lovastatin was identified in Pleurotus ostreatus, and by 1987 it was approved 
by the FDA.  
 
 There are currently six statins available for patients in Canada: atorvastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin and simvastatin. Lovastatin, simvastatin and pravastatin are 
derived from fungi while the other three are synthetic. Their relative potency, from highest to 
lowest, is: rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin, and fluvastatin
7
. 
Relative risk rates when comparing statins are considered to be highest in rosuvastatin, then 
atorvastatin and simvastatin and lastly pravastatin and lovastatin
8
. Relative potency of statins 
seems to correlate with relative risk, with the exception of fluvastatin
8
.  
 
Mechanism of statins. HMG-CoA reductase is a catalyst in the early biosynthesis of cholesterol 
which derives mevalonate by a 4-electron reduction of HMG-CoA. All statins work by 
effectually inhibiting this step by competing for the catalytic binding domain for the HMG-CoA 
in the HMG-CoA reductase molecule. Statins are competitive inhibitors of HMG-CoA reductase 
and, when competing with HMG-CoA, have a significantly higher binding affinity with the 
reductase molecule. The HMG-CoA-like moiety of a statin monopolizes the HMG-CoA binding 
pocket in the HMG-CoA reductase molecule and links via its O5 hydroxy group
9
. When the 
HMG-CoA moiety is in the binding pocket, the remainder of the statin structure undergoes a 
conformational change in order to maximize contact with, and binding to, amino acid residues of 
3 
 
the reductase. The number and strength of the bonds vary between statins, dictating the length 
and degree of inhibition and ultimately resulting in the level of LDL cholesterol-lowering 
efficacy. Rosuvastatin forms nine bonding interactions with the reductase, making it the most 
potent statin, followed by atorvastatin, which forms eight bonds. The fungal statins, lovastatin, 
simvastatin and pravastatin, each have six bonding interactions
9
.  
 
 Through the inhibition of HMG-CoA reductase, there is a reduction of cholesterol 
synthesis in the hepatocyte, a reduction in the cholesterol pool and subsequent up-regulation of 
the nuclear transcription factors sterol regulatory element-binding proteins, resulting in an 
increase in the transcription of LDL receptors on the hepatic cell surface. The LDL receptors link 
with apolipoprotein (apo) B and apoE on the surface of circulating LDL and very-low density 
lipoprotein particles are integrated, along with their lipid content, into the hepatocyte
10
. In 
addition, when hepatic cholesterol is converted to bile acids the LDL receptors are up-regulated 
to help with food absorption in the gastrointestinal tract.  
 
Metabolism of statins. Lipid-soluble statins are converted to water-soluble salts and glucuronide 
conjugates for elimination from the body while simvastatin, lovastatin and, to a lesser extent, 
atorvastatin are metabolized by cytochrome P450 3A4 (CYP3A4) enzymes. Numerous drugs are 
either inhibitors or substrates for this enzyme system and can result in drug-drug interactions, 
leading to increased plasma concentrations of the statin. Approximately 10% of fluvastatin and 
rosuvastatin are metabolized primarily by CYP2C9
11
, the rest remaining fairly unchanged until 
excretion. These two statins are excreted from the body largely unchanged as parent compounds 
by transporter-mediated excretion mechanisms in the liver into the feces via bile and into the 
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urine. Pravastatin is not metabolized by the P450 enzyme system. The open acid forms of several 
statins often undergo glucuronidation followed by lactonization
12
. In their lactone form, statins 
may be converted to their open acid form by an esterase enzyme and metabolized, excreted by 
bile or urine, or directly metabolized by the cytochrome P450 system. Excretion of statins 
through bile or feces is mediated by transport proteins such as OATP1B1 and multidrug 
resistance-associated protein-2.   
 
 Drug interactions in statin users must be closely monitored, as drugs often affect 
metabolism time, which in turn affects the systematic concentration of statin. Drugs inhibiting 
the CYP3A4 enzyme can interfere with the metabolism of atorvastatin, simvastatin, and 
lovastatin causing an increase in the area under the statin concentration-time curve. Drugs that 
inhibit CYP2C9 should theoretically affect the metabolism of fluvastatin, although in practice 
there are very few clinical observations of this. OATP1B1 is an inhibitor that, alongside other 
inhibitors of CYP3A4, inhibits a vital transporter by which hydrophilic statins are transported 
into the liver.  
 
 Certain fibrates, a class of drugs that lowers blood triglyceride levels, and Warfarin, an 
anticoagulant mainly used in the prevention of thrombosis and thromboembolism, have the 
potential to interact with statin therapy. The fibrate gemfibrozil can interact with the OATP1B1-
mediated transport resulting in an increase of plasma statin concentration
13
. Additionally, 
gemfibrozil interferes with the glucuronidation and lactonization of statins, promoting a higher 
concentration of open acid statins. To avoid these drug interactions, it is recommended that the 
fibrate fenofibrate is used instead to help avoid adverse effects, or the statins atorvastatin or 
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fluvastatin should be used. Warfarin-statin interactions may result in a displacement from plasma 
protein binding sites by the statin, resulting in a minor increase of prothrombin times and 
bleeding. While adverse effects are uncommon, close monitoring of the patient is recommended 
for a patient using Warfarin when lovastatin, rosuvastatin or simvastatin is added or removed 
from a regiment.  
 
7.1 Creatine kinase levels as a biomarker 
Creatine kinase is the most commonly used enzyme utilized in the diagnosis of muscle disease. 
Serum levels of CK are the most sensitive known biomarker and the best known indicator of the 
course of muscle injury
14
. In extreme cases, this muscle myopathy can manifest into 
rhabdomyolysis, showcasing a correlated increase in plasma CK levels. Using CK as a 
biomarker is an effective and non-invasive sensitivity test for various levels of muscle myopathy 
as well as myocardial infractions.  
 
CK is an enzyme found predominantly in skeletal muscle, the myocardium and the brain. 
CK catalyzes the reversible reaction of creatine, consuming ATP resulting in the production of 
phosphocreatine and ADP. CK is expressed as any of the following three isoenzymes: CK-MM, 
CK-BB, CK-MB where B represents the brain type subunit and M the muscle type subunit.  
 
 Disruption of cell membranes can release CK from the cellular cytosol into the systemic 
circulation. This elevation of plasma CK levels can be used as a biomarker for myocardial 
infarction, rhabdomyolysis, muscle dystrophy, the autoimmune myositides and in acute renal 
failure.  
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 Serum CK is a commonly used biomarker for myocardial infarction. 40% of CK in 
cardiac muscles is CK-MB. Levels of CK-MB tend to increase within 3 to 4 hours of myocardial 
necrosis, peak within a day and return to normal within 36 hours. Subsequent reinfarctions can 
be diagnosed if CK-MB levels do not begin to decline after approximately 24 hours
15
. Although 
highly effective in diagnosing acute MI, it is important not to rely solely on CK-MB as a 
biomarker, as an electrocardiogram should ultimately be used as an assessment of the patients 
risk and stability
16
. 
 
 
7.2 Patient management through evaluation of CK levels  
Clinicians often measure serum CK levels as a rough proxy for severity of statin-induced 
myotoxicity, but the correlation between symptoms and CK level remains incomplete. The 
clinical interpretation of CK level is complex and there is not yet a consensus on the definition of 
statin myopathy. The American College of Cardiology
17
, American Heart Association (AHA), 
National Heart, Lung and Blood Institute (NHLBI)
18
, the FDA
19
 and National Lipid Association 
(NLA)
20
 have each proposed different definitions for statin-related muscle effects  (Table II).  
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Table I. Definitions of statin-induced myalgia 
Clinical entity  ACC/AHA/NHLBI 2002  NLA 2006  FDA  
Myopathy General term referring to any 
disease of muscles 
Complaints of myalgia 
(muscle pain or soreness), 
weakness, and/or cramps, 
plus elevation in serum CK > 
10 × upper limit of normal 
(ULN) 
CK ≥ 10 × 
ULN 
Myalgia Muscle ache or weakness 
without CK elevation 
NA NA 
Myositis Muscle symptoms with 
increased CK 
NA NA 
Rhabdomyolysis Muscle symptoms associated 
with marked CK elevations, 
typically substantially > 10 × 
ULN and with creatinine 
elevation  
CK > 10,000 IU/l or CK > 10 
× ULN plus an elevation in 
serum creatinine or medical 
intervention with i.v. 
hydration 
CK > 50 × 
ULN and 
evidence of 
organ damage, 
such as renal 
compromise 
 
The lack of consensus on the definition of statin myopathy hinders estimation of its true 
incidence. Elevations less than threefold the upper limit of normal (ULN) are typically 
considered of little consequence. Conversely, clinicians often intervene in statin therapy (change 
dose or change drug) when CK levels exceed threefold the ULN. At present, the literature 
supports three diagnostic strata: (i) incipient myopathy (CK above 3-fold the ULN, less than 10-
fold the ULN), (ii) myopathy (CK above 10-fold the ULN, less than 50-fold the ULN), and (iii) 
rhabdomyolysis (CK above 50-fold the ULN)
21
. CK levels are not routinely measured before 
statin therapy begins. Patients are encouraged to report myalgia by a physician warning or the 
product information sheet. When CK levels are elevated, the statin is usually withdrawn, 
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although, largely due to the lack of baseline CK measurement, it is difficult to determine whether 
statin therapy or another cause is to blame. 
 
Disagreement in the definition of statin-induced muscle events impedes the precise 
estimation of its true prevalence. Because patients with a considered high susceptibility to statin 
toxicity are generally excluded from clinical trials of statins, reported adverse event rates from 
controlled trials may underestimate the true rate of these adverse effects in an unselected patient 
population. As genetic variants may play a role in elevated levels of plasma CK, it is valuable to 
analyze the SNPs in the hopes of finding a new biomarker to better diagnose CK levels in 
patients. There has been a preliminary study done at the Pharmacogenomics center, and strong 
association was found between variants in the muscle CK gene (CKM) and elevated plasma 
levels of CK. 
 
A meta-analysis of 21 clinical trials providing 180,000 person-years of follow-up found 
that myopathy, defined by muscle symptoms and CK levels above a 10-fold ULN, occurs in five 
patients per 100,000 person-years
20
. Rhabdomyolysis, defined by either CK levels above 10,000 
IU/L, CK levels above a 10-fold ULN with an elevation in serum creatinine or requirement for 
hydration therapy, occurs in 1.6 patients per 100,000 person-years
22
. Less severe manifestations 
are much more common. Although CK has long been used as a diagnostic biomarker, CK 
measurement is not always accurate for the clinical management of statin-induced myotoxicity
23
, 
and therefore more accurate tools and/or novel sensitive biomarkers are required.  
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7.3 Predictors of serum creatine kinase levels 
Although elevated levels of CK are often used as a biomarker for muscle myopathy, the expected 
level of CK in a patient is often unclear. Elevated CK levels tend to be higher in certain 
populations, and as baseline CK levels are not routinely measured due to cost and time 
limitations, it is hard to gauge what the actual effects of statins are on CK levels in a patient. 
Covariates such as gender, ethnicity, age and physical activity levels have been found to be 
highly correlated with plasma CK levels.  
 
High intensity exercise will spike CK levels for a limited amount of time, usually for a 
few days following exercise
24
. Females tend to have lower baseline levels of CK, although it has 
been suggested that females might undergo a greater spike in CK levels with physical 
activity
25,26
. It has been refuted that this increased spike in CK levels may be attributed to poor 
study design, and not actually account for the differences in genders exercising
27,28
. Although 
there is a clear correlation between serum CK levels and recent physical activity, it is unclear 
whether this spike is a good predictor of muscle damage
29
. When completing a routine measure 
of a patient’s serum CK levels, it is hard to account for the effect of physical activity in the 
measurement and whether this increase in serum CK levels is leading to muscle myopathy. 
 
Exertional rhabdomyolysis (ER) is the degradation of skeletal muscle cells caused by 
strenuous exercise. Common indicators of ER include muscle pain, myoglobinuria and an 
elevated level of CK after exercise. It is unclear why certain individuals experience ER while 
others, who participate in comparable amounts of physical activity, do not. Confounders include, 
but are not limited to, fasting, hypokalemia, certain dietary supplements, dehydration, concurrent 
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illnesses, low baseline fitness levels and extreme or repetitive exercise
30
.  Although CK is often 
used to monitor ER, correlation is unclear. Some patients with CK levels greater than 10,000 U/L 
have no overt clinical symptoms, while others with a CK level less than 5,000 U/L exhibit 
symptoms of ER
31
. One study that looked at genetic polymorphisms associated with ER found 
three noteworthy SNPs in the CKMM, ACTN3 and MYLK2 genes
32
. Another study that looked 
at association between serum CK and ER in military recruits found the SNPs IL-6 and MLCK 
37885 to be positively associated, and furthermore these SNPs were more common in 
participants of African-American descent
33
. It was noted that this association may have been due 
to genetic differences in race as opposed to differences in CK levels.  
 
Age and gender have an effect on expected serum CK levels. The average male’s baseline 
CK level is higher than the average females. Additionally, there is an age-dependant decrease of 
CK levels, seen predominantly in males
34
.  
 
Individuals of African American ancestry have been shown to have higher levels of 
creatine kinase when compared to Caucasian, Hispanic and Asian people
34
. Current standards for 
measuring muscle myopathy through CK levels disregard biological and environmental 
differences in patients. Serum CK levels are reported to be approximately 70% higher in a 
healthy Black person when compared to a healthy Caucasian
35
. A young African American male 
can be expected to experience higher than normal levels of CK levels without muscle damage, 
which is not accounted for in the above definitions of myopathy and rhabdomyolysis.  
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7.4 Adverse effects of statins 
Most patients tolerate statins well; however, 10% of patients develop muscle-related adverse 
effects
36
. The most commonly reported adverse effect of statins is muscle myotoxicity, which 
can, in the worst cases, progress to rhabdomyolysis. Other adverse effects include toxicity in the 
kidneys and liver, and may be heightened by age or concomitant medications. Accurate 
diagnosis of statin-induced myopathy is important given the large and expanding numbers of 
patients eligible for statin therapy
37
 and the fact that myalgia, or muscle pain, is one of the most 
frequent causes of discontinuation of therapy. Statins can cause a wide range of muscular 
adverse effects with no specific clinical characteristics, from non-specific myalgias to 
rhabdomyolysis
38
, with symptoms usually developing within four weeks but can be delayed up to 
four years after statin initiation.  
 
 Advocates of statin therapy believe benefits greatly outweigh risks. Myopathy and 
rhabdomyolysis are estimated to affect 1/100,000 patient-years and by monitoring altered CK 
levels these adverse effects can be minimized
39
. Monitoring and measuring statin myopathy 
includes watching for elevated levels of CK, statin dosage reduction, discontinuation, or 
switching of statin and alternative treatments, such as low-dose or alternative day (as opposed to 
daily) rosuvastatin
21
.  
 
 Hepatotoxicity, or chemically driven liver damage, manifesting in statin users as 
asymptomatic elevation of serum transaminases, hepatits, cholestasis and acute liver failure, has 
been observed in a small percentage of patients
39. Serious liver damage is extremely rare in statin 
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users, one study finding that low to moderate dosages of pravastatin, lovastatin and simvastatin 
are not associated with liver function test abnormalities
40
.  
 
 Nephrotoxocity, toxic chemicals or medications to the kidneys, is a rare adverse effect of 
statins. Studies have reported moderate proteinuria, seen in 1-2% of potent statins given at 
recommended dosages
41
. Patients with end stage renal disease are more susceptible to 
nephrotoxicity. Patients with renal dialysis see an increase in cardiovascular events but statins 
have little or no observed beneficial effects on mortality and cardiovascular events, despite a 
reduction in serum cholesterol levels
42
. The Study of Heart and Renal Protection (SHARP) found 
success in reducing major atherosclerotic events when ezetimibe 10 mg was used in addition to 
simvastatin 20 mg daily in patients with chronic kidney disease
43
.  
Table II. other rare adverse effects of statins are demonstrated in the following table
39
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7.5 Compliance with statins 
Despite reducing clinical cardiovascular end points by 30%
44
 and having a positive benefit to 
risk ratio, statins are underutilized. A recent European study estimated that 20% of patients with 
coronary heart disease do not use statins
45
. The primary reason for discontinuation of statins is  
due to muscle pain, followed by cost and then by perceived lack of efficacy
46
. If physician-
patient communication were to increase, there may be an improvement in patients adherence to a 
statin
47
. Through personalized medication and pharmacogenomics, we aim to eventually increase 
patient-doctor insight in statin therapy, henceforth increasing patient wellbeing and adherence 
while minimizing muscle adverse effects.  
 
 Patient adherence to statins is low, and even more so in geriatric patients. In elderly 
patients, most of the statin discontinuation occurs within six months of commencement and long 
term use remains low
48
.  As a result, elderly patients who discontinue may have little to no 
benefit from receiving statin therapy
49
. In order to gain insight on discontinuation, studies have 
compared two specific statins, in order to better gauge each of their adherence rates. 
Discontinuation was found to be much lower in atorvastatin than simvastatin, although it is 
unclear whether this was due to effectiveness, cost, adverse effects or another confounder
50
. It is 
difficult to gauge adherence of prescription medicine, as WHO estimates that 50% of patients do 
not take their medication as prescribed
51
.  
 
7.6 Loci associated with statin-induced myotoxicity 
Patient-related risk factors for statin-related myotoxicity include female gender, low body mass 
index, concomitant treatment with certain cytochrome P450 inhibitors, a decline in renal and 
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hepatic function, and changes in albumin and -1 glycoprotein levels with subsequent changes in 
free concentration levels of statins
21
. Statin myopathy is dose-related. An increase in statin dose 
and statin systemic exposure magnifies the risk of muscle toxicity
21
. It is speculated that there 
may be a genetic link to a patient’s susceptibility to statin adverse effects. Below is a review of 
genetic variants found in prior studies that are associated with an increase in adverse muscle 
related effects in statin users.  
 
SLCO1B1. A genome-wide study has identified common genetic variants in SLCO1B1 that are 
associated with substantial alterations in the risk of simvastatin-induced myopathy
52
. The finding 
of an association between the variant rs4149056 in the SLCO1B1 gene and statin-induced 
myotoxicity has since been replicated in both an independent trial and a practice-based 
longitudinal cohort
53,54
. Recently, the Clinical Pharmacogenomics Implementation Consortium 
published a guideline paper that discusses the relationship between rs4149056 and the clinical 
outcome for simvastatin
55
. The mechanism of statin-induced muscle injury is not completely 
understood, although several mechanisms have been suggested including isoprenoid depletion, 
decreased sarcolemmal membrane cholesterol, inhibition of ubiquinone or coenzyme Q10 
(CoQ10) synthesis, disturbed calcium metabolism or an autoimmune occurrence
21
.  
 
Other variants, such as rs4363657 located in SLOC1B1, have been found to be  
associated with a higher risk of statin induced myopathy
56
. This variant is located within intron 
11 of SLCO1B1 on chromosome 12. These two SNPs identified to be associated with statin 
metabolism, rs4363657 and rs4149056, were found to be in linkage disequilibrium (r
2
=0.97)
52
. 
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rs2306283 has been found to be borderline associated with risk of myopathy in statin users, 
validated in the SEARCH trial among the HPS subjects
52
.  
 
COQ2. 2 SNPs in the COQ2 gene that are in linkage disequilibrium were identified in a study 
that is associated with adverse muscle symptoms in statin users
57
. Statins reduce CoQ10 levels 
by inhibiting the HMG-CoA reductase and diminishing the CoQ10 transport capacity by 
decreasing LDL levels
58
 which may hinder statin mechanisms and somehow increase the 
frequency of muscle adverse affects in statin users.  
 
Another variant associated with statin induced myopathy, rs4693570, was identified in the 
COQ2 gene
59
.  
 
GATM. GATM is an enzyme required for the synthesis of creatine that encodes glycine 
aminotransferase. Since the phosphorylation of creatine is the primary downstream product of 
GATM activity, it was hypothesized that variants in GATM may affect muscle adverse effects in 
statin users. In a primary case control study, and then again in a secondary replication study, it 
was found that statin users with the minor allele at the GATM differential eQTL locus had a 
reduced incidence of myopathy
60
. rs9806699 was identified, along with 5 other loci, a cis-eQTL 
for the gene glycine amidinotransferase (GATM) that encodes the rate limiting enzyme in 
creatine synthesis
60
. Although the mechanism behind this association is unclear, a possible 
explanation could be that diminished capacity for phosphocreatine storage modifies cellular 
energy storage and adenosine monophosphate-activated protein kinase signalling
61,62
 in a manner 
that is protective against cellular stress as induced by glucose deprivation
62
 or, potentially, by 
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cholesterol depletion. It is possible that statin users may be at high risk for muscle toxicity 
partially through metabolic effects in the liver, the primary site of statin’s pharmacologic actions.  
 
ATP2B1. ATP2B1, located in chromosome 12, aids in intracellular calcium regulation and may 
play a role in statin induced myalgia. Variant rs17381194 was identified in the Statin Induction 
and Neuro-Myopathy study as being associated with intracellular calcium regulation, and thereby 
may be associated with myalgia in statin users
59
.  
 
DMPK. Statins have been found to expose mild forms of muscle dystrophy, caused by certain 
genes. DMPK is thought to be related to muscle dystrophy, and variant rs672348 in the DMPK 
gene, located in chromosome 12, may play a part in muscle related adverse effects in statin 
users
59
.   
 
ABCB1. The SNP rs2235046 (C1236T) located in the ABCB1 gene, in chromosome 7, has been 
found to be associated with elevated plasma CK levels in statin users
63,64
.  
 
ABCG2. The ABCG2 gene, located in chromosome 4, helps to limit the absorption of statins in 
the gut. The SNP rs2231142 (genotype ABCG2 c.421C>A) SNP was found to significantly 
affect the risk of atorvastatin-induced myopathy
65
.  
 
CYP2D6. The SNP rs3892097 (CYP2D6*4), located in chromosome 22, has been found to be 
associated with muscle adverse events caused by at least two structurally dissimilar HMG-CoA 
reductase inhibitors, and may be related to statin induced myopathy
66
. 
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CYP3A5. The CYP3A5 gene, located in chromosome 7, is involved in drug metabolism and 
synthesis of cholesterol. One study found the variant rs776746 (CYP3A5*3) to be associated 
with atorvastatin-induced myalgia
67
. It was found that persons who were homozygous for 
CYP3A5*3 had a greater risk for increased plasma CK levels than those that were heterozygous 
for the SNP
67
. 
 
RYR2. Mutations in RYR2, an intronic gene located in chromosome 1, may indicate an increased 
risk for muscle myopathy
68
. One study noted an increased risk for cerviastatin-induced 
rhabdomyolysis which correlated with a mutation in the SNP rs2819742.  
 
HTR3B and HTR7. People who have a lower tolerance for pain can be expected to experience 
muscle pain at a higher frequency. Two SNPs, rs2276307 SNP in the HTR3B gene, located in 
chromosome 11, and rs1935349 SNP in the HTR7 gene, located in chromosome 10, were found 
to be associated with the myalgia score in statin users
68,70
. This is thought to be due to these 
mutations which affect an individual’s pain tolerance.  
 
NOS3 and AGTR1. SNPs associated with endothelial homeostasis may be correlated to plasma 
CK levels in statin users. One study identified two variants, rs1799983 in the NOS3 gene, located 
in chromosome 7, and rs12695902 in the AGTR1 gene, located in chromosome 3
68,71
. 
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7.7 Myotoxicity reports in clinical trials 
Data from systematic reviews, meta-analyses, clinical trials, and post marketing surveillance 
indicate that statin-associated myalgia typically affects around 5.0% of patients, as myopathy in 
0.1% and as rhabdomyolysis in 0.01%. The frequency of muscle symptoms associated with statin 
therapy was evaluated in the Prediction of Muscular Risk in Observational Conditions study, an 
observational study conducted in an unselected population of 7,924 hyperlipidemic patients 
receiving high-dose statins in an outpatient setting in France
36
. Muscle-related symptoms were 
reported by 832 patients (10.5%), which is a rate at least 2 times higher than that observed in 
clinical trials involving statins (1–5%)72. The number of patients reporting muscle-related 
symptoms was the highest in those receiving simvastatin (18.2%), followed by atorvastatin 
(14.9%) and pravastatin (10.9%). Myalgia is among the leading reasons patients discontinue 
statins. It is thought that hyroliphic statins such as fluvastatin and pravastatin are less likely to 
result in muscle adverse events. The number of muscle complaint incidences varies between 
studies is mainly due to the contradictory definitions of myotoxicity.  
 
 One study that assessed the benefits and harms of early administered statins to patients 
with acute coronary syndrome found that there were no short term benefits (less than four 
months) although there were long term favourable benefits. Therefore, statins are more useful as 
a long term preventative measure against cardiovascular incidences. It was found that severe 
muscle toxicity (found in 0.13% of participants) was mostly limited to those taking 80 mg of 
simvastatin
73
. When compared to atorvastatin, cerivastatin had a higher rate of muscle myopathy 
and rhabdomyolysis
74
, which was at times fatal, and was taken off the market in 2001. Since 
statin induced myotoxocity is dose dependant, there may be some success with intermittent statin 
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dosing regimens in patients with previous intolerance due to myopathy, particularly with 
atorvastatin and rosuvastatin
75
. The efficacy of this method is questionable, as the benefits of 
statin may go down as dosage is lowered.  
 
 A study from the University of Toronto noted that there has been a shift towards 
intensive versus moderate statin therapy
76
. This shift has primarily taken place within 
atorvastatin users, and is not generalizable to other statins. This shift has led some to believe that 
statins are oftentimes excessively administered. These studies call for a more personalized 
approach to statin care
77
.  
 
 Because hypercholesterolemia is largely asymptomatic, any unpleasant effects of 
pharmacologic agents used to manage it can undermine adherence. However, patients often 
underestimate the degree to which elevated cholesterol increases their risk of coronary events. 
Given these perceptions, adverse effects, such as myalgia, can assume an important role in a 
patient’s decision to discontinue a much-needed lipid-modifying medication. Indeed, several 
studies document a significant decrease in adherence to lipid-lowering treatments over time 
among outpatients, and some indicate that patient’s perception of adverse effects is a primary 
reason for discontinuation
48,49
. Statin intolerance may substantially reduce treatment compliance 
and statin efficacy in preventing cardiovascular endpoints. Physicians, pharmacists and patients 
are often hasty to assume that a variety of common musculo-skeletal aches and pains are related 
to statin use.  
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7.8 Summary of prior project 
The Pharmacogenomics Center at the MHI conducted a case-control study on statin myotoxicity 
evaluating genetic determinants of statin-induced muscle pain. 4391 participants were recruited, 
all taking statins and half reporting muscle adverse events. 979 participants were removed for the 
following reasons: they were recruited into the study because of a history of high CK levels, they 
had a missing CK measure or they were not currently on a statin. An additional 3 outliers were 
removed.  
 
 The objective of this project was to perform a genome wide association study evaluating 
the association between CK measures and SNPs. 
 
It was found that patients with ongoing muscle pain had, on average, slightly higher 
plasma CK levels than those without a prior history of statin-induced muscle pain who generally 
tolerated high-dose statins well. In a multivariate analysis, when adjusting for factors known to 
influence CK levels including age, sex, physical activity, statin and statin dose, a significant 
difference in plasma CK levels between cases and controls (p-value = 9.90x10
-5
) was found, 
despite the fact that the majority of CK values were within the “normal” clinical range. 
 
To follow up on this observation, a genome-wide search for genetic determinants of CK 
levels in all statin users in the study population was performed. The 610quad and iselect were 
used to identify 584509 SNPs for the project. A strongly significant association signal between 
the muscle CK gene (CKM) variants and plasma levels of CK (p = 10
-16
; Figure 1) was found. 
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Figure 1. Manhattan plot showing the results of a genome-wide association study for genetic 
determinants of CK levels measured in statin users in the MHI statin study. A GLM regression 
with the natural logarithm of CK was used, with adjustment for the case-control status, the 
lab where the CK measures were taken, gender, physical activity level, age, diabetes and 
BMI.  There were 3388 participants in the statin myotoxicity case-control study that were using 
statins at the time of CK measurement. Genetic variants in the CKM gene (p=5.03x10
-16
) and 
the LILRB5 gene (p=5.71x10
-11
) were identified. 
 
The CKM variant rs11559024 encodes a missense variant (421A/G) in the 3rd exon of the 
gene causing an amino acid change at GLU83GLY, a polymorphism with a population frequency 
of 2%. This gene encodes creatinine-kinase-M which reversibly catalyzes the transfer of 
phosphate between ATP and creatine phosphate and functions as a homodimer in striated 
muscle. The two other associated variants (rs2361797 and rs406231) are located in the LILRB5 
gene, over 5M base pairs away from the CKM gene. The LILRB5 gene encodes a leukocyte 
immunoglobulin-like receptor which binds to MHC class I molecules and is involved in immune 
response. Genetic association of the LILRB5 variants by conditioning on the CKM variant 
rs11559024 provides a strongly significant signal (p=2.55x10
-11
) and is therefore expected to 
function as an independent factor from CKM. As the findings in this study are issued from a 
genome-wide investigation, it is likely that the associations found are indirect associations and 
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that the identified variants are in linkage disequilibrium with other neighbouring and potentially 
causal variants.  
 
7.9 Reason for replication in a larger cohort  
The prior project warrants a follow up study that will more finely characterize the genetic factors 
in the CKM and LILRB5 genes. Pharmacogenetics has the potential to optimize patient benefice 
from drugs by removing the ‘fixed dosage’ method and instead looking at variants in the DNA in 
order to gauge the patient’s potential benefits and adverse effects of a drug78. Replication on a 
larger cohort will help to ensure that prior finding were credible associations and not a chance 
finding or due to uncontrolled biases
79
. The current replication study on 5091 patients will 
validate prior association found with variants in the CKM and LILRB5 genes, and possibly lead 
to further discoveries, helping to pave the way towards better statin care.  
 
 Bias in a GWAS can occur for a number of reasons. One major source of bias when 
conducting genetic association tests in a population is heterogeneity, especially if the population 
has a similar ethnic background. A GWAS done for a continuous trait using a population of a 
certain ethnic background can not necessarily be applied to a population of a different ethnic 
background. Bias in a study can produce an outcome that differs from the truth, resulting in false 
negatives, false positives or inaccurate effect sizes. Hardy-Weinberg disequilibrium, genotyping 
quality, how you arrive at a population, incorrect confounders, and Winner’s curse can all cause 
bias in a GWAS. Replication studies and careful choosing of a population, as well as being 
aware of all limitations can help to reduce bias.  
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Conclusive evidence should not be drawn from one study, but rather from a study and the 
replication studies it spawns. When a regression model shows an association with a p-value 
below 0.05, this is an indicator that there may be significant correlation, but by no means a 
complete argument
80
. The probability of a study yielding true results is based on the probability 
of truth before the study was done, the statistical power of the study and the statistical 
significance of the study
81,82
. Therefore it is best if replication is shown before publishing 
findings, in order to minimize the number of contradictory publications and better further studies 
in the area.  
 
 In a preliminary genome wide association study, a phenomenon called the winner’s curse 
can arise. This refers to the regression toward the mean. Since numerous tests are done at once, a 
preliminary GWAS will report the most significant findings, or the winners, which tend to be 
inflated. When association of a rare variant is discovered, the power can be less than 1%, grossly 
inflating the effects and creating a need for further replication before confirmation of 
association
83
.  
 
Preliminary, hypothesis testing studies are a first step, and are not sufficient on their own. 
Carefully conducted replication studies are necessary, followed by a sensible meta-analysis that 
incorporates not only statistical analysis but also provides a cautious interpretation of the 
results
84
. The prior study done at the Pharmacogenomics Center of the MHI warrants a 
replication project in a larger cohort. Before confirmation of the genetic variants previously 
identified, it is necessary to test for replication in order to increase confidence that identified 
variants are not false negatives. 
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7.10 Discovery Study with the MHI Biobank 
The MHI Biobank study uses the ExomeChip from Illumina to provide genetic data of the 
coding regions of genes in participants, which allows for the testing of rare genetic variants in a 
large cohort. We propose to use this wealth of genetic data to examine these rare SNPs and their 
relation to plasma CK levels in order to potentially further validate or discover novel variants 
that were not necessarily covered in the prior study. The discovery study will ultimately pinpoint 
any genetic variants in this population that are associated with plasma CK levels, providing a 
deeper comprehension of genetic variants related to statin adverse muscle effects.  
 
The MHI Cohort is diverse in terms of age and sex and is thorough in its questionnaire 
regarding alcohol intake, dietary habits, tobacco, medication and depression. Vital signs (heart 
rate, blood pressure, weight, height, waist circumference) are obtained by a nurse, and blood, 
DNA, and plasma are collected. The self-reported physical activity is lacking in comparison to 
the WHO physical activity standards, but this pitfall has been amended for any new participants 
in the continuation of the study. Participants were recruited from MHI and at its affiliated EPIC 
centre. Over 11,000 participants have been genotyped with the Illumina ExomeChip. The MHI 
Biobank is a robust cohort that can be used for the analysis of a multitude of studies. As in any 
study, it must be noted that the cohort population was located in Montreal, so this population can 
be expected to differ in genetic makeup than a population residing elsewhere.  
 
 The ExomeChip from Illumina tests for over 270,000 genome-wide variants located in 
the exon of genes. The ExomeChip aims to create an intermediate platform which will enable 
examination of coding variants, down to singletons. Both relatively common variants currently 
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used in genotyping arrays, and exome sequencing of a very large numbers of samples are looked 
at using the ExomeChip. 
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8 RATIONAL AND HYPOTHESIS 
We hypothesize that there exist genetic variants in the coding regions of the exome that would 
regulate plasma CK levels. We further hypothesize that we would be able to detect those genetic 
variants by genetic association tests with the Illumina ExomeChip. 
 
Objective 1. We aim to test the association of genetic variants in the CKM and the LILRB5 genes 
with plasma CK levels in order to replicate the results of a prior study where those genes were 
identified.  
 
Objective 2. We aim to search for novel genetic variants in an exome-wide discovery study. The 
study will consist of two major parts: 
1. GWAS: This will look at common genetic variants (MAF>5%) 
2. SKAT: This will look at rare genetic variants (MAF<5%) 
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9 METHODS 
9.1 Study Design  
The goal of this study is to provide information that may, in the future, help to better clinical 
statin care by improving the expected CK level algorithm for a patient. Along with covariates 
already known to affect CK levels, genetic factors and the role they played were looked at that 
may help to ultimately create a new method for calculating expected CK levels of a patient. In 
doing this, one can hope to better future statin care by creating a more realistic threshold for CK 
levels and decreasing the number of patients taken off statins unnecessarily.  
 
 This study is a cohort study for a continuous trait. Data on participants was collected 
from the MHI Biobank, including both descriptive statistics and genetic data. The study was 
limited to those who had an available CK measure and participants were stratified by three 
subgroups: statin users, non statin users and all participants. The study consists of two phases: a 
replication study using 17 variants from the CKM and LILRB5 genes, both areas identified in 
a previous study conducted at the Pharmacogenomics center followed by a discovery study. The 
discovery study was genome wide, genotyping 584,509 SNPs, consisting of both a GWAS 
for common variants and a SKAT burden test for rare variants (MAF < 5%).  
 
9.2 Study population 
The MHI Hospital Cohort participants came from the MHI Biobank. This is a longitudinal cohort 
study led by Dr. Jean-Claude Tardif which was initiated in 2005 with the aim to recruit 30,000 
patients of the MHI for clinical and genetic research. Participants are recruited from different 
departments within the MHI and its affiliated EPIC centre; the largest fitness centre in Canada 
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for coronary patients and research in primary and secondary prevention. The MHI Cohort 
collects data by using a 35-page questionnaire administered by a research nurse at baseline and 
questions about demographics, personal and family medical history, physical activity, diet, 
tobacco, medication use, as well as an additional depression and hostility questionnaire. Vital 
signs (heart rate, blood pressure, weight, height, waist circumference) are obtained by the nurse 
and blood, DNA, and plasma are collected and stored at the Beaulieu-Saucier 
Pharmacogenomics Center. Patient’s health status is confirmed by the nurse by using the 
Hospital's health record and with governmental databases (RAMQ, MedEcho) for retrospective 
and prospective follow up until patient’s death. The Cohort's database is updated daily with 
patient's medical information from the hospital's electronic records and a follow-up study 
questionnaire is administered every three years. The MHI Biobank comprises of 17,000 
participants as of August 2012 with a mean follow up period of 2.8 years including over 5000 
participants who are using or have used a statin during the follow-up period. 
 
The association of genetic factors with plasma CK levels in both the replication 
(objective 1) and discovery studies (objective 2) was investigated in a subset of the MHI 
Biobank. The MHI Biobank is a large hospital-based longitudinal population of over 11,000 
patients with a wide spectrum of cardiovascular diseases who have recently had their DNA 
genotyped using the ExomeChip from Illumina. The MHI Biobank was initiated in 2005 with the 
aim of clinical and genetic research.  
 
In the present study, a sub-cohort of the original Biobank consisting of 7821 participants 
with available genotyping and CK levels was chosen of which the data of 5875 participants had 
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usable CK levels. All participants that had a creatinine level exceeding 200 mmol/L (n=85) taken 
within a month of the CK measurement used were excluded from the study. The reasoning 
behind this is that patients with severe renal impairment or muscle disease not related to statins 
should be removed from the study. To control for this, patients with a creatinine level greater 
than 200 umol/L were removed. Additional outliers were also removed using jack-knife 
residuals. Therefore, discovery study was performed on 5875 available participants including 
3677 on a statin and 2198 not on a statin. 
 
9.3 Creatine kinase 
Creatine kinase data collection. From the cohort, we used a subset of participants with available 
plasma CK levels and genetic data. CK is an enzyme and can be assayed from the blood serum 
with a detection kit. This was done in the MHI laboratory with a blood sample taken from each 
participant.  
 
Creatine kinase measurements. The most recent available CK measurement was used, using a 
selection of total CK measures (variables CKi1 and CK1 from softlab, n=43518). We have opted 
to exclude all measurements that were requested for hospitalized patients and emergency patients 
in order to exclude CK measurements. This is because measurements would be inflated by 
elevation of CK-MB, which is typically the case in patients who have suffered a recent 
myocardial infarction. Specifically, measurements requested from the following clinics were 
excluded:   
Code Clinic 
3EST 3ieme est 
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4EST 4ieme est 
5EST 5ieme est 
3CEN 3ieme centre 
PSERP projet serp-1 
PBARI projet barath 
PPRIM projet primo 
ANDG introuvable 
PPGXS génomie 
PREPA projet repare 
URG urgence 
CLDIA cl.dialyse 
4CEN 4ieme centre 
URGAM urgence ambulatoire 
5CEN 5ieme centre 
CLPGR clinique de pré greffe 
 
 
9.4 Statins 
For patients taking a statin, their dosage is related to the type of statin used. The equivalent 
dosage to atorvastatin was calculated for each participant in order to allow for comparisons 
between patients on applicable statins. The statin dosage was transformed to the equivalent 
dosage as shown in table III.  
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 Different statins use varying pathways, and therefore different statins affect statin 
induced muscle adverse effects differently. We used one all-inclusive category of statin, 
instead of stratifying by each statin type, which could be a limitation of our study. The 
majority of participants in the MHI cohort with available CK levels used atorvastatin. It has been 
found that the most hydrophilic statins, such as pravastatin and fluvastatin, are less likely to 
cause myalgia, while lipophilicone statins such as simvastatin are more likely to induce muscle 
adverse effects
85
. We did not stratify the users by statin type because most of the subsets were 
too small to preserve power.  
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Table III. Table of equivalent dosage of statins 
Atorvastatin  
equivalent 
Atorva- 
statin 
Fluva-
statin 
Lova-
statin 
Prava-
statin 
Rosuva- 
statin 
Simva- 
statin 
5 mg -- 40 mg 20 mg 20 mg -- 10 mg 
10 mg 10 mg 80 mg 40 mg 40 mg -- 20 mg 
20 mg 20 mg -- 80 mg 80 mg 5 mg 40 mg 
40 mg 40 mg -- -- -- 10 mg 80 mg 
80 mg 80 mg -- -- -- 20 mg -- 
160 mg -- -- -- -- 40 mg -- 
              
 
  
33 
 
9.5 Physical activity 
Muscle damage, often accompanied with a spike in CK levels, is commonplace after intense 
physical activity. The increase in CK levels that occurs after physical activity varies in relation to 
the type (low impact verse high impact) and the intensity of exercise. Participants in the MHI 
cohort completed a survey of their physical activity which was based off the World Health 
Organization (WHO) guidelines. The two surveys differed only in that the MHI Cohort survey 
did not take into account unpaid labour, such as gardening and household chores, that are 
commonly accepted as physical activity. This is an expected pitfall of the survey, as we have 
no way of adjusting for this and may lose some accuracy in the analysis. The MHI Cohort survey 
is being amended to adjust for this in future studies.  
 
In order to clean up data from the survey and split the participants into three classes of 
physical activity, guidelines from the WHO survey were followed. The procedure included 
calculating the metabolic minutes (a measure to combine the counts of physical and moderate 
activity) of physical activity. Using the metabolic minutes and the days of activity per week, the 
participants were split into three classes of physical activity: elevated, moderate or limited.  
 
9.6 Ethnicity and principal components 
In the MHI Hospital Cohort survey, participants were asked to choose between Caucasian, 
Hispanic, Black, Native American, Asian or other as their principal ethnicity. The vast majority 
of participants identified as Caucasian. Although self-reported ancestry is sometimes a viable 
way to stratify data in a large cohort
86
, it can have limited reliability, especially when an 
individual has more than one country of origin
87
. As the vast majority of participants identified 
as Caucasian, principal component analysis (PCA) was used. In a GWAS, a small percentage of 
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the SNPs can provide useful information on a participant’s ancestry. These ancestry informative 
markers can be used in a PCA analysis to help correct for any ancestry discrepancies
88
.  
 
9.7 Hardy-Weinberg equilibrium and linkage disequilibrium 
If a population is in Hardy-Weinberg equilibrium, allele and phenotype frequency will remain 
stable throughout generations, assuming there is no outside evolutionary influence. It is 
important to look at Hardy-Weinberg equilibrium when genotyping, as deviation from 
equilibrium may indicate genotyping errors, population stratification or, in rare cases, true 
association
89
. A goodness-of-fit test was performed on SAS 9.3 to verify that all variants were 
in Hardy-Weinberg equilibrium. 
 
Linkage disequilibrium is the non-random association of alleles at two or more loci. When 
two alleles are located near each other and are inherited together more often than expected, this 
association is called linkage disequilibrium
90
. In a traditional GWAS such as this, the one-at-a-
time SNP method increases the chances of randomness seen in associated SNPs, and can 
potentially increase the number of false positives in the study. GWAS studies can help to identify 
loci where causal relationships are suspected, but associated SNPs should be cautiously verified 
due to this increase in false positives. Linkage disequilibrium was looked at using a HapMap 
from haploview. 
 
9.8 Genetic data and cleanup 
All patients were genotyped using the IlluminaExomeChip array (version InfiniumHumanExome 
v1.0 DNA Analysis BeadChip), that tests for over 270,000 genome-wide variants located in the 
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exome of genes. Whole genome analysis was performed with 620,901 SNPs using the 
IlluminaInfinium HD Assay and the Human 610quad BeadChips (Illumina, San Diego, CA).  
 
Complementing this, a Multi-Sample iSelect Custom BeadChip was used, containing 
11,568 SNPs from candidate genes involved in lipid homeostasis, hypertension and drug 
metabolism. Control samples provided 100% consistency. Following genotype quality 
procedures and removal of 65 non-Caucasian samples, there remained 584,509 SNPs for 
analysis. All genotyping was performed at the Beaulieu-Saucier Pharmacogenomics Centre.  
 
The cleanup of genetic data was done at the Beaulieu-Saucier Pharmacogenomics Centre 
at the MHI, using the following guidelines:  
 Checked for duplicate samples, then for duplicated SNPs. 
 Completely failed SNPs were removed. 
 Poorly performing DNA samples with a genome-wide genotyping success rate < 
90% were removed, followed by SNPs with a genotyping success rate < 98%, and 
finally by removing IDs with less than 98% successful call rates. 
 All individuals with discrepancies between phenotype and genotype data for sex 
were removed. 
 SNPs with genotyping plate-bias were filtered out. 
 610quad and iselect data sets were merged. 
 Pairwise IBD was used to conduct close familial relationship checks, and all but 
one pair-member of sibling pairs and sample duplicated (IBS > .86 or IBS > 98%) 
were removed. This was based on a selection of uncorrelated SNPs (r
2
 < 0.1). 
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 The pairwise IBS matrix was used as a distance metric to identify cryptic 
relatedness among samples and sample outliers by multi-dimensional scaling 
(MDS).  The first two MDS components of each subject have been plotted. In 
order to scale the outlying distance, the genotypes were merged with those of 
HapMap CEU data (keeping only founder individuals) prior to calculating the IBS 
matrix and the MDS. 
 For each SNP, Hardy-Weinberg equilibrium was tested for, and SNPs with p-
value < 8x10
-8
 were removed. SNPs with p-value < 10
-4
 were flagged. 
 All individuals with no sex in the phenotype file or heterozygous haploid 
genotypes were removed.  
 
9.9 Summary of available variants for replication study 
In the prior project to be replicated, there were significantly associated variants found in the 
CKM and LILRB5 genes. As a result, all available variants from the CKM and LILRB5 genes in 
the ExomeChip were used. The build number for all genes in the ExomeChip is 37. There were 
12 available variants in the CKM gene and 20 available in the LILRB5 gene. In the CKM gene, 
rs11559024 was found to be significantly associated to plasma CK levels in the prior project.  
 
 
Table IV. Table of variants in CKM and LILRB5 genes available for replication study 
Chr 
Position 
(build 37) Gene SNP 
Intron/ 
exon 
Minor Allele 
Frequency 
(MAF)* 
minor 
allele
* 
major 
allele
* 
19 45810010 CKM rs142092440 exonic 0.001143 G A 
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19 45810035 CKM rs4884 exonic 0.2892 A G 
19 45810108 CKM rs199913939 exonic 0 0 A 
19 45810862 CKM rs200633759 exonic 0 0 A 
19 45815163 CKM rs17357122 exonic 0.008429 A G 
19 45818628 CKM rs377993 intronic 0.4742 A G 
19 45818750 CKM rs149872015 exonic 0.000286 A G 
19 45818809 CKM rs147574145 exonic 0.000286 A G 
19 45818825 CKM rs17875653 exonic 0.002999 C G 
19 45821183 CKM rs11559024 exonic 0.01095 G A 
19 45822809 CKM rs201048164 exonic 0.00019 A G 
19 45822882 CKM rs145633772 exonic 0.000333 A C 
19 54754667 LILRB5 rs150133483 exonic 0.000143 A C 
19 54755937 LILRB5 rs144185169 exonic 0 0 G 
19 54755955 LILRB5 rs3848614 exonic 0.000907 G C 
19 54756246 LILRB5 rs117421142 exonic 0.02247 G A 
19 54756401 LILRB5 rs139593424 exonic 0.000476 A G 
19 54756735 LILRB5 rs143517976 exonic 0.000048 A G 
19 54756767 LILRB5 rs201004751 exonic 0.000095 A G 
19 54758762 LILRB5 rs149797743 exonic 0 0 G 
19 54758810 LILRB5 rs201168501 exonic 0.000048 G A 
19 54759306 LILRB5 rs139291477 exonic 0.000238 C G 
19 54759349 LILRB5 rs199626075 exonic 0 0 A 
19 54759361 LILRB5 rs12975366 exonic 0.4355 G A 
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* MAF of MHI Hospital Cohort, calculated in PLINK   
19 54759395 LILRB5 rs145597773 exonic 0.000381 A G 
19 54759931 LILRB5 rs199539096 exonic 0.000381 C A 
19 54760105 LILRB5 rs200687007 exonic 0.00019 A G 
19 54760189 LILRB5 rs150247609 exonic 0.00019 A G 
19 54760376 LILRB5 rs144666082 exonic 0.000238 A C 
19 54760381 LILRB5 rs149664511 exonic 0.002713 A G 
19 54760453 LILRB5 rs191146326 exonic 0 0 A 
19 54761023 LILRB5 rs150778096 exonic 0.001 G C 
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9.10 Statistical analysis  
Statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC) and PLINK 
v1.07 (http://pngu.mgh.harvard.edu/~plink). The Shapiro Wilk test was used to check the 
normality of CK measures. Additionally, a goodness-of-fit test was performed to verify that all 
variants were in Hardy-Weinberg equilibrium and linkage disequilibrium (LD) was looked at 
using a HapMap from haploview. 
 
 
9.11 Regression model for replication study 
The regression model used in this analysis was based on that of the prior project. The 
replication project used the same covariates as the prior project done at the Pharmacaogenomcis 
lab while the discovery study left room for exploration of covariates. A general linear model 
(GLM) was constructed between the CK level and the additive effect x (Equation 1). 
Furthermore, a GLM with adjustment for sex, statin, age and activity levels (Equation 2) was 
constructed. The analysis was done on SAS 9.3.  
 
                        [Equation 1]  
 
                       gender     statin     age                        [Equation 2] 
 
Where x is the additive effect for each individual,     corresponds to the mean effect and    , 
  ,   ,   and    are the coefficients of x, gender, statin, age and activity levels respectively.  
 
 
40 
 
 
 
Note that the variables x is defined for the additive effect as seen below:  







alleles.minor  2 has SNP  theif1
allele,minor  one and allelemajor  one has SNP  theif0
alleles,major   twohas SNP  theif1
x
 
 
The data was stratified by three subgroups: all participants, statin users and non-statin users. 
Linear regression was run on each of these subgroups twice, once with only the additive model 
as an independent variable and then a multivariate analysis with gender, age, activity levels and 
statin dose (where applicable) as covariates.   
 
The frequencies of rare alleles among the significantly associated variants were looked at. 
 
9.12 Statistical analysis of multiple variants at a time for replication study 
This analysis looked at each associated variant, two or three at a time, to check for linkage 
equilibrium. Linkage equilibrium occurs when the genotype present at one locus is independent 
of the genotype at a second locus. A regression model was constructed, and if the two or three 
variants together were relatively similar as the model where only one variant was looked at, the 
variants were said to not be in linkage equilibrium, and we could consider them to be 
independent for this analysis. The model was run using SAS 9.3. The following equations were 
used: 
 
                     rs11559024 
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      rs12975366 
 [Equation 3] 
 
                     rs11559024 
      rs12975366 
                                                  
[Equation 4] 
 
                     rs11559024 
                    
[Equation 5] 
 
                     rs11559024 
                                                                     
[Equation 6] 
 
                     rs11559024 
      rs142092440 
      rs12975366 
    [Equation 7] 
 
                     rs11559024 
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      rs142092440 
      rs12975366 
                                                    
[Equation 8] 
 
 
9.13 Imputation analysis for replication study 
An imputation analysis allows for the accurate evaluation of association of genetic markers 
that are not directly genotyped
91
. Since variant rs2361797 (BP 54751064 build37) from the 
LILRB5 gene in chromosome 19 was identified in a previous study but not directly 
genotyped in this one, we aimed to impute data for this variant in the hopes of validating 
prior findings. Imputation of common variants is extremely accurate, and allows for the 
combination of two or more data sets, which often analyze different genetic variants. According 
to protocol, we only used SNPs with a completion rate greater than 98%. The imputation 
analysis was done using PLINK v1.07. 
 
9.14 GWAS for discovery study 
When used correctly, GWAS is a powerful tool used in identifying variants associated with 
disease in humans. In a typical GWAS, thousands of samples and their hundreds of thousands of 
SNP markers throughout the human genome are scanned. Since a GWAS scans the entire 
genome, there is the possibility of finding novel susceptibility factors, as opposed to candidate 
gene studies which only look at variants either taken at random or with a suspected association to 
the disease.  
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An analysis for principal components one and two was performed to try and account 
for ethnicity in the plasma CK levels. Ethnicity is known to be a strong confounder in genetic 
association studies. As there is a well-known difference in CK levels in some ethnic populations, 
this is relevant in the present study. This said, one must be careful as it has been observed that 
when studying rare SNPs, covariates can sometimes decrease power of the analysis
92
. Certain 
SNPs already account for factors such as gender and ethnicity, so when a covariate is added, they 
may be double counted for, resulting in a less powerful test overall. We performed the GWAS 
with principal components one and two as covariates in the hopes of increasing power for rare 
variants and minimizing false positives. 
 
When using all available variants, the QQ from the GWAS were not within the expected 
range, insinuating inflated results. This may be because the rare variants were not being properly 
accounted for in the algorithm. To adjust for this we compared the QQ plots of all available 
SNPs with QQ plots using just common SNPs that had an allele frequency greater than 5%. 
Through a comparison of variants with different MAFs, we found that the QQ plots were within 
an expected range when only looking at common variants, increasing our confidence in the 
Manhattan plots shown in the results section. Thus we used all variants with an allele frequency 
greater than 5% for the GWAS and opted to use a SKAT burden test for the rare variants. This 
method allowed for better management of inflation, as demonstrated in the QQ plots seen in the 
results section.  
 
The GWAS was done using PLINK v1.07. 
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9.15 SKAT for discovery study 
 
In order to find association of rare variants (defined in this study as less than 5% allele 
frequency) in a GWAS, the sample size must often be very large. Burden tests can be used to 
summarize the rare variants in a certain area and find association within a locus. These tests have 
been shown to be more powerful than the univariate test used in GWAS when looking at rare 
variants
93
. In a burden test, all rare variants in a given area are summarized by a single value, and 
association for this is tested. This must be implemented cautiously, as it can be expected that 
summarizing variants will increase noise in an analysis.  
 
SKAT calculates a p-value for association of rare variants in a region of a phenotype, while 
adjusting for any covariates specified. SKAT has been found to be more powerful than many 
other burden tests when analyzing rare variants genome wide
94
.  
 
The SKAT analysis was done using PLINK v1.07. 
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10 RESULTS  
10.1 Participants 
A sub-cohort was chosen from the MHI Biobank consisting of participants with available 
genotyping and CK levels. After exclusions, there were 5875 available participants, 3677 on a 
statin and 2198 not on a statin. Participants were excluded if they had a creatinine level 
exceeding 200 mmol/L and then further exclusions were made based on an analysis of 
studentized residuals.  
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Figure 2. Flowchart of participants from MHI Biobank that tracks where participants were 
excluded  
 
10.2 Descriptive statistics from MHI Biobank 
Frequency and percentages were calculated for categorical variables while mean, median, 
standard deviation and ranges were looked at for continuous variables. Only participants with an 
available CK level were used. 
  
Genotyped individuals 
after cleanup n=10,525 
plasma CK level taken 
n=7,821 individuals and 
43,581 measurements 
Usable participants 
n=5,960 individuals 
and 26,590 
measurements 
After exclusions, with 
covariates n=5,875 
Non statin Users 
n=2,198 Statin users n=3,677 
Creatinine level > 
200mmol/L n=85 
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Table V. Descriptive statistics of participants from the MHI Biobank after exclusions 
    All Statin Users Non-Statin Users 
    n=5875 n=3677 n=2198 
Age (years) Mean (Std) 
68.38 (±10.59) 70.55 (±8.81) 64.76 (±12.21) 
Men n (%) 3959 (67%) 2718 (74%) 1241 (56%) 
Race n (%)    
     Caucasian   5773 (98.4%) 3624 (98.7%) 2149 (97.9%) 
     Hispanic   30 (0.5%) 15 (0.4%) 15 (0.7%) 
     Black   36 (0.6%) 18 (0.5%) 18 (0.8%) 
     Asian   16 (0.3%) 8 (0.2%) 8 (0.4%) 
     Native American   0 (0%) 0 (0%) 0 (0%) 
     Other   10 (0.2%) 5 (0.1%) 5 (0.2%) 
Creatine kinase (U/L) Mean (Std) 106.38 (±89.37) 106.77 (±80.70) 105.74 (±102.25) 
 Min/Max 7/2120 7/2120 8/2120 
ln(Creatine kinase)  Mean (Std) 4.47 (±.60) 4.49 (±.59) 4.44 (±.61) 
  Min/Max 1.95/7.66 1.95/7.47 2.08/7.66 
Physical activity n (%)    
     Low  1734 (41.3%) 1133 (40.1%) 601 (43.8%) 
     Moderate  1699 (40.4%) 1178 (41.7%) 521 (37.9%) 
     Elevated   768 (18.3%) 517 (18.3%) 251 (18.3%) 
*13 participants identified with two ethnicities, and were categorized as other 
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Table VI. Overview of the 3516 patients currently taking statins, with statin dosage available, 
and with a creatinine level under 200 mmol/L 
  Dosage (mg) Atorvastatin 
Equivalent (mg) 
 n (%) Mean Mean  
Current statin    
Atorvastatin 2113 (57%) 34.50 6.46 
Fluvastatin 36 (1%) 51.67 5.02 
Lovastatin 9 (0%) 20.06 7.67 
Pravastatin 274 (7%) 30.67 72.40 
  Rosuvastatin 892 (24%) 18.10 15.12 
Simvastatin 353 (10%) 30.23 6.46 
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Ethnicity and principal components.  Principal components were used to control for ethnic 
discrepancies between individuals. As seen in the graphs below, by using just the first two 
principal components one can reduce discrepancies between self-reported questionnaires and 
genetic ethnicity.  
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Figure 4. Principal components 1 and 2, marked by self reported ethnicity 
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Figure 3. The principal components from the MHI cohort data using PCA as a proxy for 
ethnicity. Charts, from left to right, represent DAL-Outcomes (Roche) and proportional 
cumulative explained variance of the first 10 components. The third principal component seems 
to be an inflection point on the screen plot, so in further analysis only the first two principal 
components were used. 
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11 RESULTS FOR REPLICATION STUDY - Objective 1 
 
11.1 Results of replication model 
There are 17 SNPs available for testing, so the Bonferroni-adjusted significance threshold was 
set to 0.05/17=0.002941.  
 
 
There are 5091 genotyped participants available for analysis after exclusions. In the discovery 
study there were 5875 participants. The replication study was done before all the participants 
were genotyped, explaining the smaller population size.  
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Table VIIa. Association analysis between log(CK levels) and SNPs for all participants in the 
MHI Hospital Cohort. The multivariate analysis with a general linear model of CK  is performed  
first with additive effect only. P-values surpassing the Bonferoni threshold are highlighted. 
 
Chr 
Position 
(build 37) Gene SNP 
No ajustement 
N p-value R-squared* 
19 45810010 CKM rs142092440 5091 0.000156 0.002805 
19 45810035 CKM rs4884 5091 0.73213 0.000023 
19 45815163 CKM rs17357122 5091 0.008329 0.001367 
19 45818628 CKM rs377993 5091 0.446943 0.000114 
19 45818750 CKM rs149872015 5091 0.167151 0.000375 
19 45818809 CKM rs147574145 5091 0.656476 0.000039 
19 45818825 CKM rs17875653 5091 0.573712 0.000062 
19 45821183 CKM rs11559024 5091 8.05x10
-19
 0.015306 
19 54755955 LILRB5 rs3848614 5091 0.71948 0.000025 
19 54756246 LILRB5 rs117421142 5091 0.425831 0.000125 
19 54756401 LILRB5 rs139593424 5091 0.178514 0.000356 
19 54759306 LILRB5 rs139291477 5091 0.810846 0.000011 
19 54759361 LILRB5 rs12975366 5091 4.28x10
-21
 0.017307 
19 54759395 LILRB5 rs145597773 5091 0.531165 0.000077 
19 54759931 LILRB5 rs199539096 5091 0.983371 0.000085 
19 54760381 LILRB5 rs149664511 5091 0.883995 0.0000042 
19 54761023 LILRB5 rs150778096 5091 0.324039 0.000191 
 
*R-squared is the coefficient of determination for the regression model including the genetic 
term only  
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VIIb. Association analysis between log(CK levels) and SNPs for all participants in the MHI Hospital Cohort. The multivariate 
analysis with a general linear model of CK  is performed  first with additive effect, gender, age and physical activity (two adjusted 
versions, one with statin yes/no and one with equivalent dosage of statins). P-values surpassing the Bonferoni threshold are 
highlighted. 
Gene  SNP 
Adjusted GLM (statin yes/no) Adjusted GLM (statin equivdos) 
N 
Global p-
value p-value 
R-
squared N 
Global p-
value p-value R-Squared 
CKM rs142092440 3960 1.87x10
-80
 5.06824x10
-06
 0.093182 3960 4.05x10
-80
 6.04301x10
-06
 0.092825 
CKM rs4884 3960 5.33x10
-76
 0.760151119 0.088416 3960 9.62x10
-76
 0.730986936 0.088141 
CKM rs17357122 3960 1.00x10
-76
 0.062563017 0.089194 3960 1.88x10
-76
 0.064443715 0.088902 
CKM rs377993 3960 5.40x10
-76
 0.792186263 0.088411 3960 9.78x10
-76
 0.770811158 0.088133 
CKM rs149872015 3960 1.22x10
-76
 0.079296937 0.089105 3960 2.28x10
-76
 0.081909345 0.088812 
CKM rs147574145 3960 5.34x10
-76
 0.765684026 0.088415 3960 9.82x10
-76
 0.780829741 0.088132 
CKM rs17875653 3960 2.91x10
-76
 0.251484862 0.088698 3960 5.52x10
-76
 0.265340131 0.0884 
CKM rs11559024 3960 8.10x10
-91
 9.95869x10
-17
 0.104166 3960 1.29x10
-90
 8.64888x10
-17
 0.103953 
LILRB5 rs3848614 3960 4.44x10
-76
 0.495481621 0.088502 3960 8.22x10
-76
 0.508639223 0.088215 
LILRB5 rs117421142 3960 3.98x10
-76
 0.408770468 0.088552 3960 7.23x10
-76
 0.404392051 0.088274 
LILRB5 rs139593424 3960 2.83x10
-76
 0.241041739 0.088712 3960 5.17x10
-76
 0.241457728 0.08843 
LILRB5 rs139291477 3960 5.24x10
-76
 0.719233949 0.088425 3960 9.72x10
-76
 0.754801237 0.088136 
LILRB5 rs12975366 3960 3.50x10
-92
 4.00975x10
-18
 0.105601 3960 4.36x10
-92
 2.71181x10
-18
 0.1055 
LILRB5 rs145597773 3960 3.83x10
-76
 0.381955307 0.088571 3960 7.11x10
-76
 0.392817672 0.088282 
LILRB5 rs199539096 3960 5.55x10
-76
 0.916017295 0.088397 3960 1.01x10
-75
 0.907607254 0.088117 
LILRB5 rs149664511 3960 2.52x10
-76
 0.204241401 0.088766 3960 4.63x10-
-76
 0.20644526 0.088482 
LILRB5 rs150778096 3960 4.46x10
-76
 0.501270815 0.088499 3960 8.18x10
-76
 0.504128214 0.088217 
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*R-squared is the coefficient of determination for the regression model including the genetic term, sex, physical activity, age and 
statin dose (either yes/no or atorvastatin equvilant dosage) 
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Table VIII. Association analysis between log(CK levels) and SNPs for participants in the MHI Hospital Cohort taking statins. The 
multivariate analysis with a general linear model of CK  is performed  first with additive effect only and second with additive effect, 
gender, statin dose, age and physical activity. P-values surpassing the Bonferoni threshold are highlighted. 
Chr 
Position 
(build 37) Gene  
 No adjustment Adjusted GLM 
SNP N p-value R-squared N 
Global p-
value p-value R-Squared 
19 45810010 CKM rs142092440 3446 0.001217 0.003034 2673 6.43x10
-47
 0.000472 0.082719 
19 45810035 CKM rs4884 3446 0.828302 0.000014 2673 2.58x10
-44
 0.865465 0.078512 
19 45815163 CKM rs17357122 3446 0.009412 0.001956 2673 2.36x10
-45
 0.026989 0.080192 
19 45818628 CKM rs377993 3446 0.129494 0.000667 2673 1.62x10
-44
 0.322431 0.078841 
19 45818750 CKM rs149872015 3446 0.149883 0.000602 2673 5.70x10
-45
 0.078273 0.079574 
19 45818809 CKM rs147574145 3446 0.615888 0.000073 2673 2.49x10
-44
 0.755146 0.078536 
19 45818825 CKM rs17875653 3446 0.469796 0.000152 2673 1.19x10
-44
 0.206306 0.079055 
19 45821183 CKM rs11559024 3446 4.19x10
-15
 0.017733 2673 2.40x10
-54
 7.25x10
-12
 0.094594 
19 54755955 LILRB5 rs3848614 3446 0.944248 0.0000014 2673 2.06x10
-44
 0.486798 0.07867 
19 54756246 LILRB5 rs117421142 3446 0.962001 0.00000066 2673 1.89x10
-44
 0.41625 0.078731 
19 54756401 LILRB5 rs139593424 3446 0.218915 0.000439 2673 1.66x10
-44
 0.336723 0.078822 
19 54759306 LILRB5 rs139291477 3446 0.769741 0.000025 2673 2.22x10
-44
 0.564758 0.078617 
19 54759361 LILRB5 rs12975366 3446 9.39x10
-14
 0.015986 2673 5.97x10
-56
 1.6x10
-13
 0.097135 
19 54759395 LILRB5 rs145597773 3446 0.479128 0.000145 2673 1.95x10
-44
 0.439394 0.078709 
19 54759931 LILRB5 rs199539096 3446 0.932539 0.0000021 2673 2.57x10
-44
 0.852214 0.078515 
19 54760381 LILRB5 rs149664511 3446 0.524918 0.000117 2673 2.02x10
-44
 0.469468 0.078683 
19 54761023 LILRB5 rs150778096 3446 0.961878 0.00000066 2673 2.60x10
-44
 0.899056 0.078508 
*The first R-squared is the coefficient of determination for the regression model including the genetic term, and the second is 
including the genetic term, sex, physical activity, age and statin atorvastatin equvilant dosage 
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Table IX. Association analysis between log(CK levels) and SNPs for participants in the MHI Hospital Cohort not taking statins. The 
multivariate analysis with a general linear model of CK  is performed  first with additive effect only and second with additive effect, 
gender, age and physical activity. P-values surpassing the Bonferoni threshold are highlighted. 
Chr 
Position 
(build 37) Gene SNP 
No adjustment Adjusted GLM 
N p-value R-squared* N 
Global p-
value p-value R-Squared* 
19 45810010 CKM rs142092440 1642 0.035658 0.002688 1287 8.75x10
-35
 0.003283 0.123893 
19 45810035 CKM rs4884 1642 0.882256 0.000013 1287 5.94x10
-33
 0.794537 0.118006 
19 45815163 CKM rs17357122 1642 0.352934 0.000526 1287 5.95x10
-33
 0.799412 0.118004 
19 45818628 CKM rs377993 1642 0.368015 0.000494 1287 3.99x10
-33
 0.349906 0.118561 
19 45818825 CKM rs17875653 1642 0.997037 0.0000000084 1287 5.98x10
-33
 0.817759 0.117996 
19 45821183 CKM rs11559024 1642 
1.48x10
-
05
 0.011375 1287 8.47x10
-38
 1.86x10
-06
 0.133484 
19 54755955 LILRB5 rs3848614 1642 0.587221 0.00018 1287 6.04x10
-33
 0.856411 0.117982 
19 54756246 LILRB5 rs117421142 1642 0.187937 0.001057 1287 6.06x10
-33
 0.86995 0.117978 
19 54756401 LILRB5 rs139593424 1642 0.519905 0.000253 1287 3.68x10
-33
 0.307514 0.118676 
19 54759361 LILRB5 rs12975366 1642 
7.65x10
-
09
 0.020143 1287 4.20x10
-37
 1.01x10
-05
 0.131282 
19 54759931 LILRB5 rs199539096 1642 0.899592 0.0000097 1287 8.76x10
-34
  0.117959 
19 54760381 LILRB5 rs149664511 1642 0.220883 0.000914 1287 3.05x10
-33
 0.232979 0.118939 
19 54761023 LILRB5 rs150778096 1642 0.134263 0.001367 1287 2.19x10
-33
 0.147969 0.1194 
rs149872015, exm1480276, rs147574145 and rs145597773 were removed since no minor alleles were represented in the data when 
only patients not on statin were used. rs199539096 does not have a p-value for adjusted model because no minor alleles were 
represented in the data. 
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*The first R-squared is the coefficient of determination for the regression model including the genetic term, and the second is 
including the genetic term, sex, physical activity and age  
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 Table X. Mean serum CK values by genotype of the associated variants in the CKM and LILRB5 genes in MHI Hospital Cohort 
 
Mean ± standard deviation;  N/A: not available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Statin users (n=3448) Statin non-users (n=1465) All participants (n=5093) 
Gene Variant Genotype N Mean CK (U/L) N Mean CK (U/L) N Mean CK (U/L) 
CKM rs142092440 
GG 0 N/A 0 N/A 0 N/A 
AG 10 52.70±4.38 3 40.33±1.20 13 49.85±19.51 
AA 3438 106.09±81.31 1642 103.36±103.01 5080 105.21±88.91 
CKM rs11559024 
GG 0 N/A 0 N/A 0 N/A 
AG 66 59.24±13.47 42 66.86±8.86 108 62.20±40.70 
AA 3382 106.84±81.62 1603 104.20±103.85 4985 105.99±89.37 
LILRB5 rs12975366 
GG 661 93.44±65.03 315 84.17±66.88 976 90.45±0.57 
AG 1714 103.40±74.76 811 103.08±58.13 2525 103.30±0.59 
AA 1073 117.67±96.15 519 115.10±127.50 1592 116.83±0.61 
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The general trend seen in table X is that as the number of rare alleles increase, the mean CK 
level decreases. This holds true for all four variants. However for SNP rs12975366 in the 
LILRB5 gene, the populations mean CK is best represented by the heterozygous genotype, 
with homozygotes showing either an increase or a decrease in CK. In this SNP, occurrences of 
the minor allele are common. Over 50% of the population has at least one minor allele. The 
participants who do not have either of these minor alleles tend to have above average plasma CK 
levels. The overall average level of CK in the 5093 patients is 105.07 U/L. 
 
 
 
11.2 Linkage disequilibrium analysis 
Haploview was used to look at linkage disequilibrium for the variants used in the replication 
study.  
 
60 
 
 
 
 
 
Figure 5. Linkage disequilibrium of available SNPs in the CKM and LILRB5 gene obtained from 
Haploview. The above chart looks at the r
2 
between variants of the 5093 participants from the 
MHI Hospital Cohort. All SNPs are in Hardy-Weinberg equilibrium. Each two different 
SNPs are in linkage disequilibrium. 
 
61 
 
11.3 Statistical analysis of multiple variants 
The following analysis aims to find whether two SNPs are independent. Since there are SNPs 
from both the LILRB5 gene and CKM gene, it is hypothesized that these two SNPs will exhibit 
independence. All equations used are shown in section 9.12.   
 
As seen in tables XI and XII, the most significant  association between CK measures and 
the two SNPs is  in all participants, then statin users, and lastly non-statin users. The R-squared is 
slightly higher in non statin users than statin users. This follows the same general trend as in 
tables VII – IX. These two SNPs appear to be independent. The greatest amount of variability in 
plasma CK that could be explained was 15%, by using a model that includes the genetic variants 
in CKM and LILRB5, gender, age, and physical activity in non-statin users.  
 
Similar conclusions can be drawn using tables XIII to XVI. 
 
This further supports the haplomap that the two SNPs are independent.  
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1. rs11559024 in CKM and rs12975366 in LILRB5 (equations 3 and 4)  
Table XI. Association analysis between ln(CK levels) and SNPs rs11559024 and rs12975366 genotypes stratified by statin/no 
statin/all participants in the MHI Hospital Cohort. The multivariate analysis with a general linear model of CK  is performed  first with 
genotypes only and second with additive effect, gender, statin dose, age and physical activity.  
 SNPs 
rs11559024 rs12975366 
Estimate Standard error Estimate Standard error 
Statin user additive effect  
0.59 0.07 0.11 0.01 
adjusted additive effect  
0.55 0.08 0.12 0.02 
Non statin 
user 
additive effect  
0.42 0.09 0.13 0.02 
adjusted additive effect  
0.44 0.09 0.10 0.02 
All 
participants 
additive effect  
0.53 0.06 0.12 0.01 
adjusted additive effect  
0.51 0.06 0.11 0.01 
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Table XII. Variance explained for each of the stratified models in Table XII summarized by R-squared. 
Dependent R-squared 
Coefficient of 
variation 
Root of mean 
squared error Mean Category 
ln(CK levels) 0.04 12.83 0.57 4.48 additive effect in statin users 
ln(CK levels) 0.11 12.04 0.54 4.49 adjusted additive effect in statin users 
ln(CK levels) 0.03 13.57 0.60 4.42 additive effect in non statin users 
ln(CK levels) 0.15 12.54 0.55 4.40 adjusted additive effect in non statin users 
ln(CK levels) 0.03 13.08 0.58 4.46 additive effect in all patients 
ln(CK levels) 0.12 12.24 0.55 4.46 adjusted additive effect in all patients 
*The R-squared is the coefficient of determination for the regression model including the genetic term in the unadjusted model, and 
the genetic term, sex, physical activity, age and statin atorvastatin equivilant dosage in the adjusted model.  
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2. rs11559024 and rs142092440 in CKM (equations 5 and 6) 
Table XIII. Association analysis between log(CK levels) and SNPs rs11559024 and rs12975366 genotypes stratified by statin/no 
statin/all participants in the MHI Hospital Cohort. The multivariate analysis with a general linear model of CK  is performed  first with 
genotypes only and second with additive effect, gender, statin dose, age and physical activity. 
 SNPs 
rs11559024 rs142092440 
Estimate Standard error Estimate Standard error 
Statin user additive effect  
0.57 0.07 0.61 0.18 
adjusted additive effect  
0.53 0.08 0.62 0.17 
Non statin 
user 
additive effect  
0.41 0.09 0.74 0.35 
adjusted additive effect  
0.44 0.09 0.97 0.32 
All 
participants 
additive effect  
0.57 0.07 0.61 0.18 
adjusted additive effect  
0.53 0.08 0.62 0.17 
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Table XIV. Variance explained for each of the stratified models in Table XIV summarized by R-squared. 
Dependent R-squared 
Coefficient of 
variation 
Root of mean 
squared error Mean Category 
ln(CK levels) 
0.02 12.93 0.58 4.48 
additive effect in statin users 
ln(CK levels) 
0.10 12.14 0.54 4.49 
adjusted additive effect in statin users 
ln(CK levels) 
0.01 13.70 0.60 4.42 
additive effect in non statin users 
ln(CK levels) 
0.14 12.60 0.55 4.40 
adjusted additive effect in non statin users 
ln(CK levels) 
0.02 13.19 0.59 4.46 
additive effect in all patients 
ln(CK levels) 
0.11 12.34 0.55 4.46 
adjusted additive effect in all patients 
*The R-squared is the coefficient of determination for the regression model including the genetic term in the unadjusted model, and 
the genetic term, sex, physical activity, age and statin atorvastatin equivilant dosage in the adjusted model.  
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3. rs12975366 in LILRB5, rs11559024 and rs142092440 in CKM (equations 7 and 8) 
Table XV. Association analysis between log(CK levels) and SNPs rs11559024, rs12975366 and exm 1480239 genotypes stratified 
by statin/no statin/all participants in the MHI Hospital Cohort. The multivariate analysis with a general linear model of CK  is 
performed  first with genotypes only and second with additive effect, gender, statin dose, age and physical activity. 
 SNPs 
rs11559024 rs142092440 rs12975366 
Estimate Standard error Estimate Standard error Estimate Standard error 
Statin user 
additive 
effect  
0.59 0.07 0.58 0.18 0.11 0.01 
adjusted 
additive 
effect  
0.55 0.08 0.60 0.17 0.11 0.01 
Non statin 
user 
additive 
effect  
0.42 0.09 0.69 0.35 0.12 0.02 
adjusted 
additive 
effect  
0.44 0.09 0.93 0.32 0.10 0.02 
All 
participants 
additive 
effect  
0.53 0.06 0.60 0.16 0.11 0.01 
adjusted 
additive 
effect  
0.51 0.06 0.68 0.15 0.11 0.01 
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Table XVI. Variance explained for each of the stratified models in Table XVI summarized by R-squared. 
Dependent R-squared 
Coefficient of 
variation 
Root of mean 
squared error Mean Category 
ln(CK levels) 0.04 12.82 0.57 4.48 additive effect in statin users 
ln(CK levels) 0.12 12.02 0.54 4.49 adjusted additive effect in statin users 
ln(CK levels) 0.03 13.56 0.60 4.42 additive effect in non statin users 
ln(CK levels) 0.15 12.50 0.55 4.40 adjusted additive effect in non statin users 
ln(CK levels) 0.04 13.07 0.58 4.46 additive effect in all cases 
ln(CK levels) 0.13 12.21 0.54 4.46 adjusted additive effect in all cases 
*The R-squared is the coefficient of determination for the regression model including the genetic term in the unadjusted model, and 
the genetic term, sex, physical activity, age and statin atorvastatin equivilant dosage in the adjusted model.  
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As expected, the significant SNPs in the CKM and LILRB5 genes exhibit independence. The 
two SNPs in the CKM gene seem to be somewhat dependant.  
 
11.4 Results from imputation analysis 
The imputation analysis was done but unfortunately the SNP of interest (rs2361797) had an 
extremely low completion rate of 4.18%, as seen in table XVII. Since protocol calls only for 
SNPs with a completion rate over 98%, this value was much too low to force into the rest of the 
analysis, and therefore the SNP could not be tested for replication using this method.  
 
We opted to continue to conduct the association test between CK levels in the SNPs 
where completion rate was above 98% in the off chance that any of these imputations may 
surpass the threshold of significance and potentially find novel variants. The imputation analysis 
used 53,301 variants between position 52272131 and 57182204 on chromosome 19, build 37. 
52,535 of these variants were imputed, 766 were genotyped.  
 
The imputation analysis was done using an earlier version of the MHI Biobank data. The 
new data set has an additional 718 new participants which was not in the earlier version. There 
were 6009 participant with usable CK levels used in this analysis, but hospitalized and 
emergency participants were not excluded. This is a potential pitfall of the Manhattan plot seen 
in figure 7. These participants may have had CK measurements that were inflated by elevation of 
CK-MB. To control for this, jackknife residuals were removed, excluding a further 19 
participants.  
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Table XVII. Information on imputation of SNP rs2361797 
SNP position Null Geno 
Completion 
(%) 
rs2361797 54751064 9777 426 4.18 
 
 
 
 
 
Figure 6. Manhattan plot showing the results for genetic determinants of CK levels measured in 
all participants in the MHI cohort study on chromosome 19 between position 52272131 and 
57182204 (build 37) including variants from the imputation analysis. A GLM regression with the 
natural logarithm of CK was used, with adjustment for components 1 and 2.  A genetic 
variants in the LILRB5 gene (p= 6.01x10
-15
) was identified on rs12975366. 
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Figure 7. QQ plot corresponding to figure 1 for all participants in the MHI cohort study. A 
GLM regression with the natural logarithm of CK was used with adjustment for principal 
components 1 and 2.   
 
 
  
71 
 
The goal of this imputation was to look at position 54751064 (build 37) located in 
chromosome 19, but unfortunately this exact location could not be analyzed. The closest 
imputations were at 54751043 and 54751166. There were no new findings from this imputation 
analysis. 
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12 RESULTS FOR THE DISCOVERY STUDY - Objective 2 
 
12.1 GWAS Results  
For the GWAS, the analysis was limited to variants with a MAF > 5% in order to limit bias due 
to unequal variance in small genotype categories which can cause inflation of the statistics. 
Instead, we used a SKAT burden test to test the rare variants for association with plasma CK 
levels. The GWAS was conducted on three separate subgroups: all participants, statin users and 
non statin users. Participants removed in genetic data cleanup were not used. Additional 
phenotypic outliers were removed immediately before the analysis using jack-knife for residuals 
(n=4 for all participants, n=2 for statin users, n=4 for non statin users).  
 
Figures 9, 11 and 13 are Manhattan plots showing results of the genome-wide association study 
for serum CK levels in statin users showing significant (in red) association signals in the LILRB5 
gene region. Each dot represents the -log10 P value for the genetic association using a multiple 
regression model adjusted for 2 principal components for genetic ancestry. Only variants with a 
MAF>5% were used. The dotted line shows the significance threshold. 
 
Figures 10, 12 and 14 are the corresponding QQ-plots to the Manhattan plots. The two QQ-plots 
that were overlaid are: all variants and variants with a MAF>95%. Since rare variants can have 
been shown to cause inflation, and there was inflation when all variants were used, we used the 
variants with a MAF>95% in the analysis and used SKAT to test the rarer variants.   
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Figure 8. Manhattan plot showing the results of a genome-wide association study for genetic 
determinants of CK levels measured in all participants (n=5809) in the MHI cohort study. Only 
variants with MAF > 5% were used. A GLM regression with the natural logarithm of CK was 
used, with adjustment for components 1 and 2.  The genetic variant rs12975366 in the 
LILRB5 gene (p=1.44x10
-23
) was identified. 
 
Figure 9. QQ plot corresponding to figure 8 and compared with a QQ plot of all variants, 
common SNPs with greater than 5% allele frequency for all participants in the MHI cohort 
study. A GLM regression with the natural logarithm of CK was used with adjustment for 
principal components 1 and 2.   
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Figure 10. Manhattan plot showing the results of a genome-wide association study for genetic 
determinants of CK levels measured in statin users (n=3673) in the MHI cohort study. Only 
variants with MAF > 5% were used. A GLM regression with the natural logarithm of CK was 
used, with adjustment for components 1 and 2. The genetic variant rs12975366 in the 
LILRB5 gene (p=3.87x10
-14
) was identified. 
 
 
Figure 11. QQ plot corresponding to figure 10 and compared with a QQ plot of all variants, 
common SNPs with greater than 5% allele frequency for statin users in the MHI cohort study. A 
GLM regression with the natural logarithm of CK was used with adjustment for principal 
components 1 and 2.  
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Figure 12. Manhattan plot showing the results of a genome-wide association study for genetic 
determinants of CK levels measured in non-statin users (n=2134) in the MHI cohort study. 
Only variants with MAF > 5% were used. A GLM regression with the natural logarithm of CK 
was used, with adjustment for components 1 and 2.  The genetic variant rs12975366 in the 
LILRB5 gene (p=7.9x10
-11
) was identified. 
 
Figure 13. QQ plot corresponding to figure 12 and compared with a QQ plot of all variants, 
common SNPs with greater than 5% allele frequency for non-statin users in the MHI cohort 
study. A GLM regression with the natural logarithm of CK was used with adjustment for 
principal components 1 and 2.   
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12.2 Results of SKAT 
For the SKAT analysis, only rare variants (MAF < 5%) were used. The beta weighted graph was 
looked at, and components 1 and 2 were used as covariates. The same subgroups were used as in 
the GWAS: all participants, statin users and non statin users.  
 
Figures 15, 17 and 19 are Manhattan plots showing results of the sequence kernel association 
test for serum CK levels in statin users showing significant (in red) association signals in the 
CKM gene. Each dot represents the -log10 P value for the genetic association using a multiple 
regression model adjusted for 2 principal components for genetic ancestry. The dotted line shows 
the significance threshold. Participants removed in genetic data cleanup were not used. 
Additional outliers were removed immediately before the analysis using jack-knife residuals 
(n=4 for all participants, n=2 for statin users, n=4 for non statin users). 
 
Figures 16, 18 and 20 are the corresponding QQ-plots to the Manhattan plots.  
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Figure 14. Manhattan graph showing the results for a beta weighted SKAT analysis for all 
participants (n=5349) from the MHI hospital Cohort, rare SNPs only, with adjustment for C1 
and C2, with intergenic genes. A genetic variant in the CKM gene (p=1.59x10
-23
) was found. 
 
Figure 15. QQ plot corresponding figure 14 for the beta weighted SKAT analysis for all 
participants from the MHI hospital Cohort, rare SNPs only, with adjustment for C1 and C2, 
with intergenic genes. 
78 
 
Table XVIII. This table expands upon regions that surpassed the significant threshold level in the SKAT analysis where all 
participants were looked at, adjusted for genetic components 1 and 2 
Gene chr Position 
(build=37) 
SNP Alleles 
(minor/major) 
MAF Homozygote 
rare/ 
heterozygote 
(count) 
 Type of 
mutation* 
Mutation* P-value 
from 
SKAT 
CKM 19 45810010 rs142092440 G/A 0.00128 0/13 stop-lost Synonymous SNV 1.6x10
-23
 
CKM 19 45815163 rs17357122 A/G 0.00846 1/89 missense Synonymous SNV 1.6x10
-23
 
CKM 19 45818750 rs149872015 A/G 0.00019 0/2 missense Synonymous SNV 1.6x10
-23
 
CKM 19 45818809 rs147574145 A/G 0.000095 0/2 missense Nonsynonymous SNV 1.6x10
-23
 
CKM 19 45818825 rs17875653 C/G 0.00314 0/31 missense Synonymous SNV 1.6x10
-23
 
CKM 19 45821183 rs11559024 G/A 0.0114 0/118 missense Nonsynonymous SNV 1.6x10
-23
 
*from ANNOVAR (openbioinformatics.org/annovar, build hg19) 
SNV stands for single nucleotide variant 
 
The variant rs11559024 in the CKM gene, located in chromosome 19, was identified in the replication study done at the 
Pharmacogenomics lab, and therefore it is likely that this is in fact an actual association, and not just a false positive.  
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Figure 16. Manhattan graph showing the results for a beta weighted SKAT analysis for statin 
users (n=3403) from the MHI hospital Cohort, rare SNPs only, with adjustment for C1 and C2, 
with intergenic genes. A genetic variant in the CKM gene (p=2.55x10
-16
) was found.  
 
 
Figure 17. QQ plot corresponding to figure 16 for the beta weighted SKAT analysis for statin 
users from the MHI hospital Cohort, rare SNPs only, with adjustment for C1 and C2, with 
intergenic genes. 
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Table XIX. This table expands upon regions that surpassed the significant threshold level in the SKAT analysis where statin users 
were looked at, adjusted for genetic components 1 and 2 
Gene chr Position 
(build=37) 
SNP Alleles 
(minor/major) 
MAF Homozygote 
rare/ 
heterozygote 
(count) 
 Type of 
mutation* 
Mutation* P-value 
from 
SKAT 
CKM 19 45810010 rs142092440 G/A 0.00128 0/10 stop-lost Synonymous SNV 2.6x10
-16
 
CKM 19 45815163 rs17357122 A/G 0.00846 1/58 missense Synonymous SNV 2.6x10
-16 
CKM 19 45818750 rs149872015 A/G 0.00019 0/1 missense Synonymous SNV 2.6x10
-16 
CKM 19 45818809 rs147574145 A/G 0.000095 0/2 missense Nonsynonymous SNV 2.6x10
-16 
CKM 19 45818825 rs17875653 C/G 0.00314 0/24 missense Synonymous SNV 2.6x10
-16 
CKM 19 45821183 rs11559024 G/A 0.0114 0/70 missense Nonsynonymous SNV 2.6x10
-16 
*from ANNOVAR (openbioinformatics.org/annovar, build hg19) 
SNV stands for single nucleotide variant 
 
 
The variant rs11559024 in the CKM gene, located in chromosome 19, was identified in the replication study done at the 
Pharmacogenomics lab, and therefore it is likely that this is in fact an actual association, and not just a false positive.  
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Figure 18. Manhattan graph showing the results for a beta weighted SKAT analysis for non 
statin users (n=1944) from the MHI hospital Cohort, rare SNPs only, with adjustment for C1 
and C2, with intergenic genes. Genetic variants in the CKM gene (p=1.46=x10
-7
) and the 
KLHL18 gene (p=8.82x10
-8
) were found.  
 
 
Figure 19. QQ plot for beta weighted SKAT analysis for non statin users from the MHI hospital 
Cohort, rare SNPs only, with adjustment for C1 and C2, with intergenic genes 
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Table XX. This table expands upon regions that surpassed the significant threshold level in the SKAT analysis where non-statin users 
were looked at, adjusted for genetic components 1 and 2. 
Gene chr Position 
(build=37) 
SNP Alleles 
(minor 
/major) 
MAF Homozygote 
rare/ 
heterozygote 
(count) 
 Type of 
mutation* 
Mutation* P-value 
from 
SKAT 
KLHL18 3 47374680 rs147834934 A/G 0.00019 0/2 missense Synonymous SNV 8.8x10
-08
 
KLHL18 3 47374744 rs143338649 A/G 0.000048 0/0 missense Synonymous SNV 8.8x10
-08
 
KLHL18 3 47378058 rs139767015 A/G 0.000095 0/1 missense Nonsynonymous SNV 8.8x10
-08
 
CKM 19 45810010 rs142092440 G/A 0.00128 0/3 stop-lost Synonymous SNV 1.5x10
-07
 
CKM 19 45815163 rs17357122 A/G 0.00846 0/31 missense Synonymous SNV 1.5x10
-07
 
CKM 19 45818750 rs149872015 A/G 0.00019 0/1 missense Synonymous SNV 1.5x10
-07
 
CKM 19 45818809 rs147574145 A/G 0.000095 0/0 missense Nonsynonymous SNV 1.5x10
-07
 
CKM 19 45818825 rs17875653 C/G 0.00314 0/7 missense Synonymous SNV 1.5x10
-07
 
CKM 19 45821183 rs11559024 G/A 0.0114 0/48 missense Nonsynonymous SNV 1.5x10
-07
 
*from ANNOVAR (openbioinformatics.org/annovar, build hg19) 
SNV stands for single nucleotide variant 
 
It is unlikely the KLHL18 gene is in fact a true positive, given the low representation of genetic variants in the gene in this population. 
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12.3 Candidate genes of statin-induced myotoxocity  
A literature review of genetic variants associated with statin-induced muscle myotoxicity 
(presented in introduction) has identified numerous variants. Although our study was not 
designed to assess statin-induced myotoxicity, we find it of relevance to report on the association 
results with plasma CK levels, as CK is a common biomarker of myotoxicity. The table below is 
an overview of these variants identified in prior studies and their affiliated p-values for 
association with plasma CK levels from the GWAS and SKAT analyses.  
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Table XXI. Table of candidate genes associated with statin-induced myotoxicity found in a literature review. The table includes p-
values from the GWAS; p-values below 0.05 are highlighted. Variants were only included in the chart if they had a MAF > 0.05 in the 
MHI Hospital Cohort. 
Gene chr 
Position 
(build 37) SNP 
Alleles 
(minor 
/major) MAF* 
Type of 
mutation** Mutation** 
P-value  from GWAS 
all 
participants 
statin 
users 
non 
statin 
users 
RYR2 1 237841390 rs34967813 G/A 0.3054 missense 
synonymous 
SNV 
0.7551 0.2658 0.1151 
RYR2 1 237266603 rs7554607 G/A 0.4543 intron NULL 0.06218 0.305 0.131 
RYR2 1 237271632 rs2485579 A/G 0.1344 intron NULL 0.1428 0.3805 0.304 
RYR2 1 237911004 rs2819770 A/G 0.2685 intron NULL 0.2015 0.09982 0.9426 
RYR2 1 237921596 rs1464461 G/A 0.3914 intron NULL 0.03751 0.01456 0.8229 
RYR2 1 237990122 rs2819742 A/G 0.4012 intron NULL 0.6775 0.8432 0.3319 
AGTR1 3 148460700 rs380400 G/A 0.133 
untranslated-
3 
NULL 0.8201 0.7638 0.8063 
ABCG2 4 89026109 rs2725264 G/A 0.07074 intron NULL 0.4821 0.3886 0.9723 
NOS3 7 150704843 rs891511 A/G 0.3167 intron NULL 0.3161 0.205 0.9571 
CYP3A5 7 99266318 rs4646450 A/G 0.1565 intron NULL 0.4847 0.4524 0.898 
ABCB1 7 87160618 rs2032582 A/C 0.457 missense 
nonsynonymous 
SNV 
0.9922 0.8936 0.8844 
ABCB1 7 87229440 rs9282564 G/A 0.09943 missense 
nonsynonymous 
SNV 
0.4458 0.9008 0.2867 
ABCB1 7 87220886 rs3789243 A/G 0.493 intron NULL 0.5207 0.9571 0.2676 
HTR3B 11 113803028 rs1176744 C/A 0.3338 missense 
synonymous 
SNV 
0.3121 0.8777 0.04759 
ATP2B1 12 90008959 rs2681472 G/A 0.1639 intron NULL 0.4618 0.8405 0.2853 
ATP2B1 12 90013089 rs2681492 G/A 0.164 intron NULL 0.5035 0.919 0.2748 
SLCO1B1 12 21329738 rs2306283 G/A 0.4327 missense 
synonymous 
SNV 
0.6255 0.7039 0.7843 
SLCO1B1 12 21329813 rs11045819 A/C 0.1687 missense 
synonymous 
SNV 
0.3113 0.547 0.4613 
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SLCO1B1 12 21331549 rs4149056 G/A 0.1621 missense 
nonsynonymous 
SNV 
0.5747 0.3202 0.5106 
SLCO1B1 12 21331625 rs2291075 A/G 0.4117 
coding-
synon 
nonsynonymous 
SNV 
0.8761 0.6642 0.6645 
SLCO1B1 12 21391976 rs34671512 C/A 0.05982 missense 
synonymous 
SNV 
0.4207 0.4394 0.7993 
SLCO1B1 12 21317791 rs4149032 A/G 0.3631 intron NULL 0.985 0.9359 0.8539 
SLCO1B1 12 21368722 rs4363657 G/A 0.1691 intron NULL 0.4515 0.2868 0.6749 
GATM 15 45661678 rs1288775 T/A 0.2513 missense 
nonsynonymous 
SNV 
0.2520 0.05954 0.5143 
DMPK 19 46275976 rs527221 G/C 0.108 missense 
nonsynonymous 
SNV 
0.2061 0.8083 0.1072 
*of MHI Hospital Cohort, calculated in PLINK 
**from ANNOVAR (openbioinformatics.org/annovar, build hg19) 
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Table XXII. Table of candidate genes associated with statin-induced myotoxicity found in a literature review. The table includes gene-
based p-values from the SKAT analysis; p-values below 0.05 are highlighted. Variants were only included in the chart if they had a 
MAF > 0.0001 and <0.05 in the MHI Hospital Cohort. 
Gene chr 
P-value from SKAT 
all participants statin users non statin users 
RYR2 1 0.886491 0.842326 0.768509 
AGTR1 3 0.446288 0.946719 0.42878 
COQ2 4 0.696129 1 0.584439 
ABCG2 4 0.801945 0.711438 0.838153 
NOS3 7 0.13698 0.156989 0.653147 
CYP3A5 7 0.990837 0.987342 0.972358 
ABCB1 7 0.535148 0.279578 0.575275 
HTR7 10 0.059676 0.187646 0.297454 
HTR3B 11 0.00116 0.026969 0.078215 
ATP2B1 12 1 1 0.700123 
SLCO1B1 12 0.543457 0.191031 0.943387 
GATM 15 0.777022 0.687016 0.293927 
DMPK 19 0.767762 0.440695 0.640323 
CYP2D6 22 0.414223 0.188027 0.732096 
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13 CONCLUSION 
13.1 Key results 
The first objective of this work was to replicate prior findings of association between the CKM 
and LILRB5 gene and plasma CK levels by using data from over 5000 participants to the MHI 
Biobank Cohort. We report finding a significant association with the same CKM variant 
(rs11559024) as the prior finding. This strengthens the argument that the rare allele at 
rs11559024 in the CKM gene is associated with a decrease in plasma CK (p-value=8.05x10
-19 
without adjustment; and p-value=9.96x10
-17 
in the adjusted model). An additional SNP, 
rs142092440 in the CKM gene was also identified in the present study (p-value=0.00016, 
without adjustment). Previously, two intronic SNPs in the LILRB5 gene (rs2361797 and 
rs406231) were found to be associated with plasma CK levels. Although these SNPs are not 
present on the data from the ExomeChip in our data set,  an additional SNP in the LILRB5 
gene, rs12975366, was found to be associated with plasma CK levels (p-value=4.28x10
-21
, 
without adjustment). Together, those findings add strong evidence that supports the replication 
of the association of CKM and LILRB5 with plasma CK levels.  
 
 The second objective of this work was to conduct a genome wide discovery study with 
plasma CK levels by using over 5000 participants from the MHI Biobank Cohort. Analyses 
conducted with adjustment for ethnic ancestry with the inclusion of principal components 1 and 
2 also support association in the LILRB5 gene, rs1297366 (p-value=1.44x10
-23
), which looked 
at all common variants (MAF > 5%). The SKAT analysis, which looked at rare variants 
replicated finding in the CKM gene (p-value=1.59x10
-23
). We are unsure of which variant(s) 
are causing this association, although rs142092440 causes a stop lost mutation, and 
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rs147574145 and rs11559024 are nonsynonomous so these variants are likely candidates. 
rs11559024 was identified in the prior project at the Pharmacogenomics lab, so this may be a 
causal variant or associated with a causal variant in the locus. The SKAT analysis identified a 
novel variant in the KLHL18 gene among the non statin users (p-value=3.66x10
-08
). The 
MAF of genetic variants in KLHL18 gene in the MHI Biobank Cohort was very low, and 
requires replication in a larger cohort where more of the rare alleles are present.  
 
 Statin users had, on average, a higher plasma CK level than non statin users. Participants 
who had a rare allele from the associated variants in the CKM and LILRB5 genes had, on 
average, lower CK levels. Furthermore, when two rare alleles were present, these average CK 
levels were even lower. Carriers of these rare variants may have a reduced risk of elevated CK 
levels while on a statin.   
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Table XXIII. Summary table of SNP rs12975366 located in the LILRB5 gene in chromosome 19 identified in the GWAS analysis  
 
Beta (95% CI) Standard error P-value  
MAF of MHI 
Cohort 
Global MAF (1000 
Genome) 
All participants -0.12 (-0.14, -0.09) 0.01 1.44x10
-23
 
0.44 0.2663 Statin users -0.11 (-0.14, -0.08) 0.01 3.87x10
-14
 
Non statin users -0.12 (-0.16, -0.09) 0.02 7.90x10
-11
 
 
 
 
 
 
 
 
Table XXIV. Summary table of SNP variants identified in the SKAT analysis variants surpassing the significance threshold  
 
Chr Gene SNP 
Position 
(build 37) 
Type of 
mutation* Mutation* P-value  
MAF of 
MHI 
Cohort 
Global 
MAF 
(1000 
Genome) 
All 
participants 
19 CKM 
rs142092440 45810010 stop-lost Synonymous SNV 
1.6x10
-23
 
 
0.00128 0.0009 
rs17357122 45815163 missense Synonymous SNV 0.00846 0.0041 
rs149872015 45818750 missense Synonymous SNV 0.00019  
rs147574145 45818809 missense 
Nonsynonymous 
SNV 
0.000095 0.0009 
rs17875653 45818825 missense Synonymous SNV 0.00314 0.003 
rs11559024 45821183 missense 
Nonsynonymous 
SNV 
0.0114 0.006 
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Statin users 19 CKM 
rs142092440 45810010 stop-lost Synonymous SNV 
2.6x10
-16
 
 
0.00128 0.0009 
rs17357122 45815163 missense Synonymous SNV 0.00846 0.0041 
rs149872015 45818750 missense Synonymous SNV 0.00019  
rs147574145 45818809 missense 
Nonsynonymous 
SNV 
0.000095 0.0009 
rs17875653 45818825 missense Synonymous SNV 0.00314 0.003 
rs11559024 45821183 missense 
Nonsynonymous 
SNV 
0.0114 0.006 
Non statin 
users 
3 KLHL18 
rs147834934 47374680 missense Synonymous SNV 
8.8x10
-08
 
 
0.00019  
rs143338649 47374744 missense Synonymous SNV 0.000048  
rs139767015 47378058 missense 
Nonsynonymous 
SNV 
0.000095  
19 CKM 
rs142092440 45810010 stop-lost Synonymous SNV 
1.5x10
-07
 
 
0.00128 0.0009 
rs17357122 45815163 missense Synonymous SNV 0.00846 0.0041 
rs149872015 45818750 missense Synonymous SNV 0.00019  
rs147574145 45818809 missense 
Nonsynonymous 
SNV 
0.000095 0.0009 
rs17875653 45818825 missense Synonymous SNV 0.00314 0.003 
rs11559024 45821183 missense 
Nonsynonymous 
SNV 
0.0114 0.006 
*from ANNOVAR (openbioinformatics.org/annovar, build hg19) 
SNV stands for single nucleotide variant 
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14 DISCUSSION 
14.1 Limitations 
The MHI Biobank is a longitudinal study with a growing array of data, and although large, has 
limiting factors. There is a genetic bias, as all participants were recruited from within Montreal, 
and for the most part self-identified as Caucasian. In order to answer the MHI questionnaire, 
participants had to be proficient in either English or French, resulting in the exclusion of all 
allophones that could not speak either of these languages. We would expect allophones to be 
made up predominately of immigrants, so when allophones are excluded this could further 
homogenize the cohort. To try and account for this, we used genetic variants that can further 
pinpoint a more exact ethnic makeup of each individual. As in all cohort studies, there is a risk 
that this cohort has a different genetic makeup than another, and that the genetic variants 
identified in this study that are associated with plasma CK are different from those found in 
another cohort. In order to reduce chances of this, we compared findings to prior studies. As this 
is a fairly large replication, we hope to account for as many ethnic minorities as possible and 
reduce errors that genetic heterogeneity may incur.  
 
The ExomeChip from Illumina only looks at the exome of the genome. Exome 
sequencing is cost effective but fails to identify variants found in the coding region of genes 
which affect protein function. Whole genome sequencing can identify many more variants, but is 
currently not time or cost effective although it may be a standard approach in the future. This 
said, the exome still represents a portion of the genome that can be used to identify variants with 
a large effect size and makes way for a valuable study as long as limitations are realized.  
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The MHI Biobank includes the prevalence rate of statin users, but not the incidence 
rate. This may create a bias in the study as it is probable that some participants were put on 
statins and subsequently removed after the occurrence of adverse muscle effects. Optimally, 
these participants should have their CK level used from when they were on the statin and be 
included in the statin user subgroup as it is likely they have genetic variants influencing their CK 
levels. In addition, many participants in the MHI Biobank are on concomitant medicine that may 
impact their statin dosage or CK levels. The incidence rate of statin usage among participants 
would have been a worthwhile marker to know, but only current medication is recorded in the 
MHI Biobank. 
 
When using a hospital cohort, it is important to be aware of general biases that may arise. 
A hospital cohort, such as the MHI Biobank, often has a higher incidence of sickness, is 
more homogenous and more medicated than a general population. This may incur biases 
when studies are used to assess a general population.  
 
We stratified all useable participants as either statin users or non users. We did not 
further stratify the statin users by statin type, which has been found to affect the risk of a 
statin user developing muscle related adverse effects. We did not find any change in statistical 
significance when we tried to stratify participants by statin type. Furthermore, the vast majority 
of participants used atorvastatin while only a very small percentage used fluvastatin or lovastatin. 
Stratification by statin type is something that could be looked at in future studies.  
 
14.2 Study strengths 
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A GWAS is a useful research tool which allows a project to be designed without knowing the 
biological pathway of the trait. A GWAS can potentially find multiple novel candidate genes 
with one analysis, or further validate genetic variants identified in prior studies. When used 
correctly and with caution, a GWAS is a powerful statistical method. The discovery project used 
a large cohort to identify novel variants and further confirm association in previously replicated 
genetic variants. This project paid close attention to STrengthening the REporting of Genetic 
Associations (STREGA) guidelines when conducting all aspects of the analysis. STREGA is 
considered to be the gold standard when it comes to conducting a GWAS. It was written by 
approximately 30 epidemiologists, geneticists, statisticians and journal editors as well as the 
general community of researchers, journal editors and stakeholders providing guidelines on all 
aspects of genetic association tests. We used SREGA alongside replication in order to reduce 
bias and conduct the most statistically powerful test possible. 
 
 
14.3 Interpretations 
This study replicated prior findings of variants in both the CKM and LILRB5 genes. When 
present, and even more so in the homozygote rare type, these variants appear to decrease CK 
levels. The LILRB5 gene has a minor allele that is extremely common while the variant in the 
CKM gene is considerably rarer. As this is a replication study, the coupling of pre-existing 
studies with similar findings, a large cohort population and highly significant p-values gives 
evidence for this not being a false positive, but instead a strong candidate for variants that could 
be used for CK management in a clinical setting. Using CK as a biomarker for adverse muscle 
effects, one can hope to use genetic variants in the diagnosis and prognosis of muscle myopathy 
in statin users.  
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 The influence of each genetic variant is quite small, accounting for only a small 
percentage of change in predicting plasma CK levels. Although these genetic variants could 
be a useful tool in a clinical setting, they are not powerful enough on their own and should be 
coupled with pre-existing methods for predicting plasma CK levels in patients.  
 
 The variants in the LILRB5 gene and CKM gene make for strong candidates for true 
variation in plasma CK levels. It should be noted that these variants do not appear to help 
predict plasma CK levels in statin users or non-users by more than a few percent.  
 
 Variants identified in other studies were not necessarily replicated in this cohort 
study. Previously, there has been significant association, often replicated in multiple studies, that 
shows association between CK levels and myotoxocity in statin users in genes including 
SLCO1B1, GATM, CYP3A4 and CYP2D6. None of these findings were replicated in the GWAS 
or SKAT analysis presented in this paper. Association may not have been detectable due to the 
fact that we did not always test for the exact SNP or because SNPs previously found to be 
associated with muscle myotoxicity are not necessarily expected to be associated with CK levels.  
 
14.4 Generalizability 
Personalized pharmacogenomics aims to bring an individualized medical plan for each patient 
based on their genome. As this is a relatively new area of research, it is necessary to be thorough 
and sure of the findings before implementing them in a clinical setting. This study is one of many 
needed in order to bring personalized statin care to an individual in a clinical setting.  
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 Once these variants in the CKM and LILRB5 genes are either refuted or confirmed, a 
sensitivity analysis can help develop an algorithm that takes into account genetic variants and 
provides a personalized reference level of plasma CK for each patient to be used in a clincia 
setting. We are far from this point, as complex gene interactions are hard to interpret, and this 
report is just one of the many necessary on the road to understanding the effects of genetic 
variants on CK levels in statin users.  
 
14.5 Future Studies 
This replication study confirms genetic variants associated with muscle adverse effects 
among statin users in the MHI Biobank. A major limitation of this study is the homogeneity of 
the population. A future study in a different cohort with a different ethnic makeup is a necessary 
next step. Future studies in different cohorts could further test these variants, as well as look at 
replicated variants found in the discovery study of this project. 
 
14.6 Relevance of the genes 
CKM 
Creatine kinase (CK) catalyzes the reversible transfer of high energy phosphates between 
ATP/ADP and creatine systems. CK is important for normal energy homeostasis and exerts 
several integrated functions, including temporary energy buffering, metabolic capacity, energy 
transfer and metabolic control. CK level and activity are clinically important and CK serves as a 
reliable biomarker for several diseases including myocardial infarction, rhabdomyolysis, 
muscular dystrophy and autoimmune myositis. There is only limited documentation of 
polymorphisms in the CKM gene in the literature.
95,96
 Wu et al. have reported on the finding of 
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the point mutation E79G in CKM in two acute myocardial infarction patients with muscle CK 
activity deficiency.
19 
This variant is situated 12 base pairs upstream from variant rs11559024 
(Glu83Gly) reported in our study. 
LILRB5 
LILRB5 is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is 
found in a gene cluster at chromosomal region 19q13.4.
97
 LIR subfamily B receptors are 
expressed on immune cells where they bind to MHC class I molecules on antigen-presenting 
cells and inhibit stimulation of an immune response. The protein is an integral membrane protein 
with receptor activity and contains four extracellular immunoglobulin-like domains and the 
rs2361797 variant causes a missense (D -> G) mutation in its third domain. The protein also 
includes two immunoreceptor tyrosine-based inhibition motifs and three phosphorylation sites in 
its cytoplasmic part.
98
 The LILRB5 gene presents multiple transcript variants encoding different 
isoforms and is highly expressed in skeletal muscle, liver and gallbladder.
99
 Mass spectrometry 
has detected the protein in plasma, liver and aorta and this plasmatic protein has been ascertained 
in the HUPO plasma proteome project.
99,100
 Furthermore, we could not find evidence of LILRB5 
modulation by statins.
101
 There was no report in the literature until our work for possible 
implication of this gene in human disease, but the implication of immunity in inter-individual 
variation in CK is not entirely new. Inter-individual variability in CK levels is influenced by the 
rate of CK leakage from injured muscle fibers into the circulation but it is possible that a portion 
of the variability is also due to the rate of CK clearance from the circulation.
102-104
 CK clearance 
occurs via the mononuclear phagocytic system in the liver and via Fc receptors that mediate the 
endocytosis of immune complexes. CK immune complexes are found in the blood and are 
97 
 
commonly referred to as macro CK type 1, which is a complex formed by an immunoglobulin, 
often IgG, and a CK isoenzyme, often CK-BB
102,105
.  
KLHL18  
KLHL18 is a gene that, in humans, encodes the kelch-like protein 18. KLHK genes have been 
found to be responsible for many Mendelian diseases and are possibly associated with certain 
cancers
106
, but there is currently no literature supporting its association to plasma CK levels. 
Since this locus was identified only for the statin subgroup, and there were very few minor 
alleles available, it is not excluded at this point that this could be a false positive. It has been 
suggested that for the loci in a SKAT anaylsis containing 4 or less allele observations, the results 
are likely biased
107
, as is the case which this the KLHL18 gene which has only 3 allele 
observtions. Further investigations as part of a replication study will be necessary to confirm the 
validity of this finding.  
  
98 
 
15 REFERENCES 
1 Pignone, M., Phillips, C. & Mulrow, C. Use of lipid lowering drugs for primary 
prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 321, 983-
986 (2000). 
2 Fletcher, G. F. et al. Efficacy of drug therapy in the secondary prevention of 
cardiovascular disease and stroke. Am J Cardiol 99, 1E-35E, 
doi:10.1016/j.amjcard.2007.02.001 (2007). 
3 Allen Maycock, C. A. et al. Statin therapy is associated with reduced mortality across all 
age groups of individuals with significant coronary disease, including very elderly 
patients. Journal of the American College of Cardiology 40, 1777-1785 (2002). 
4 Ray, K. K. et al. Statins and all-cause mortality in high-risk primary prevention: a meta-
analysis of 11 randomized controlled trials involving 65,229 participants. Archives of 
internal medicine 170, 1024-1031, doi:10.1001/archinternmed.2010.182 (2010). 
5 Law, M. R., Wald, N. J. & Rudnicka, A. R. Quantifying effect of statins on low density 
lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-
analysis. Bmj 326, 1423, doi:10.1136/bmj.326.7404.1423 (2003). 
6 Endo, A. The origin of the statins. 2004. Atherosclerosis. Supplements 5, 125-130, 
doi:10.1016/j.atherosclerosissup.2004.08.033 (2004). 
7 Shepherd, J., Hunninghake, D. B., Barter, P., McKenney, J. M. & Hutchinson, H. G. 
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of 
rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering 
goals. The American journal of cardiology 91, 11C-17C; discussion 17C-19C (2003). 
99 
 
8 Hoffman, K. B., Kraus, C., Dimbil, M. & Golomb, B. A. A survey of the FDA's AERS 
database regarding muscle and tendon adverse events linked to the statin drug class. PloS 
one 7, e42866, doi:10.1371/journal.pone.0042866 (2012). 
9 Istvan, E. S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA 
reductase. Science 292, 1160-1164, doi:10.1126/science.1059344 (2001). 
10 Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol 
homeostasis. Science 232, 34-47 (1986). 
11 McTaggart, F. et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. The American journal of 
cardiology 87, 28B-32B (2001). 
12 Prueksaritanont, T. et al. Mechanistic studies on metabolic interactions between 
gemfibrozil and statins. The Journal of pharmacology and experimental therapeutics 301, 
1042-1051 (2002). 
13 Shitara, Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfibrozil and its glucuronide inhibit 
the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated 
hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the 
mechanism of the clinically relevant drug-drug interaction between cerivastatin and 
gemfibrozil. The Journal of pharmacology and experimental therapeutics 311, 228-236, 
doi:10.1124/jpet.104.068536 (2004). 
14 Bohlmeyer, T. J., Wu, A. H. & Perryman, M. B. Evaluation of laboratory tests as a guide 
to diagnosis and therapy of myositis. Rheumatic diseases clinics of North America 20, 
845-856 (1994). 
100 
 
15 Chattington, P., Clarke, D. & Neithercut, W. D. Timed sequential analysis of creatine 
kinase in the diagnosis of myocardial infarction in patients over 65 years of age. Journal 
of clinical pathology 47, 995-998 (1994). 
16 Karras, D. J. & Kane, D. L. Serum markers in the emergency department diagnosis of 
acute myocardial infarction. Emergency medicine clinics of North America 19, 321-337 
(2001). 
17 Brancaccio, P., Maffulli, N. & Limongelli, F. M. Creatine kinase monitoring in sport 
medicine. Br Med Bull 81-82, 209-230, doi:10.1093/bmb/ldm014 (2007). 
18 Pasternak, R. C. et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of 
Statins. Circulation 106, 1024-1028 (2002). 
19 Sewright, K. A., Clarkson, P. M. & Thompson, P. D. Statin myopathy: incidence, risk 
factors, and pathophysiology. Curr Atheroscler Rep 9, 389-396 (2007). 
20 McKenney, J. M., Davidson, M. H., Jacobson, T. A., Guyton, J. R. & National Lipid 
Association Statin Safety Assessment Task, F. Final conclusions and recommendations of 
the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97, 
89C-94C, doi:10.1016/j.amjcard.2006.02.030 (2006). 
21 Jacobson, T. A. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis 
and management of myalgia. Mayo Clinic proceedings. Mayo Clinic 83, 687-700, 
doi:10.4065/83.6.687 (2008). 
22 Law, M. & Rudnicka, A. R. Statin safety: a systematic review. The American journal of 
cardiology 97, 52C-60C, doi:10.1016/j.amjcard.2005.12.010 (2006). 
101 
 
23 Rallidis, L. S., Fountoulaki, K. & Anastasiou-Nana, M. Managing the underestimated 
risk of statin-associated myopathy. International journal of cardiology, 
doi:10.1016/j.ijcard.2011.07.048 (2011). 
24 Baird, M. F., Graham, S. M., Baker, J. S. & Bickerstaff, G. F. Creatine-kinase- and 
exercise-related muscle damage implications for muscle performance and recovery. 
Journal of nutrition and metabolism 2012, 960363, doi:10.1155/2012/960363 (2012). 
25 Amelink, G. J., Koot, R. W., Erich, W. B., Van Gijn, J. & Bar, P. R. Sex-linked variation 
in creatine kinase release, and its dependence on oestradiol, can be demonstrated in an in-
vitro rat skeletal muscle preparation. Acta physiologica Scandinavica 138, 115-124 
(1990). 
26 Komulainen, J., Koskinen, S. O., Kalliokoski, R., Takala, T. E. & Vihko, V. Gender 
differences in skeletal muscle fibre damage after eccentrically biased downhill running in 
rats. Acta physiologica Scandinavica 165, 57-63 (1999). 
27 Rinard, J., Clarkson, P. M., Smith, L. L. & Grossman, M. Response of males and females 
to high-force eccentric exercise. Journal of sports sciences 18, 229-236, 
doi:10.1080/026404100364965 (2000). 
28 Clarkson, P. M. & Hubal, M. J. Exercise-induced muscle damage in humans. American 
journal of physical medicine & rehabilitation / Association of Academic Physiatrists 81, 
S52-69, doi:10.1097/01.PHM.0000029772.45258.43 (2002). 
29 Manfredi, T. G. et al. Plasma creatine kinase activity and exercise-induced muscle 
damage in older men. Medicine and science in sports and exercise 23, 1028-1034 (1991). 
30 Melli, G., Chaudhry, V. & Cornblath, D. R. Rhabdomyolysis: an evaluation of 475 
hospitalized patients. Medicine 84, 377-385 (2005). 
102 
 
31 Chevion, S. et al. Plasma antioxidant status and cell injury after severe physical exercise. 
Proceedings of the National Academy of Sciences of the United States of America 100, 
5119-5123, doi:10.1073/pnas.0831097100 (2003). 
32 Deuster, P. A. et al. Genetic polymorphisms associated with exertional rhabdomyolysis. 
European journal of applied physiology 113, 1997-2004, doi:10.1007/s00421-013-2622-
y (2013). 
33 Landau, M. E. et al. Investigation of the relationship between serum creatine kinase and 
genetic polymorphisms in military recruits. Military medicine 177, 1359-1365 (2012). 
34 Neal, R. C., Ferdinand, K. C., Ycas, J. & Miller, E. Relationship of ethnic origin, gender, 
and age to blood creatine kinase levels. Am J Med 122, 73-78, 
doi:10.1016/j.amjmed.2008.08.033 (2009). 
35 Brewster, L. M., Coronel, C. M., Sluiter, W., Clark, J. F. & van Montfrans, G. A. Ethnic 
differences in tissue creatine kinase activity: an observational study. PloS one 7, e32471, 
doi:10.1371/journal.pone.0032471 (2012). 
36 Bruckert, E., Hayem, G., Dejager, S., Yau, C. & Begaud, B. Mild to moderate muscular 
symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. 
Cardiovascular drugs and therapy / sponsored by the International Society of 
Cardiovascular Pharmacotherapy 19, 403-414, doi:10.1007/s10557-005-5686-z (2005). 
37 Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with 
elevated C-reactive protein. N Engl J Med 359, 2195-2207, doi:NEJMoa0807646 [pii] 
10.1056/NEJMoa0807646 (2008). 
38 Harper, C. R. & Jacobson, T. A. Evidence-based management of statin myopathy. Curr 
Atheroscler Rep 12, 322-330, doi:10.1007/s11883-010-0120-9 (2010). 
103 
 
39 Maji, D., Shaikh, S., Solanki, D. & Gaurav, K. Safety of statins. Indian journal of 
endocrinology and metabolism 17, 636-646, doi:10.4103/2230-8210.113754 (2013). 
40 de Denus, S., Spinler, S. A., Miller, K. & Peterson, A. M. Statins and liver toxicity: a 
meta-analysis. Pharmacotherapy 24, 584-591 (2004). 
41 Agarwal, R. Effects of statins on renal function. The American journal of cardiology 97, 
748-755, doi:10.1016/j.amjcard.2005.09.110 (2006). 
42 Palmer, S. C. et al. HMG CoA reductase inhibitors (statins) for dialysis patients. The 
Cochrane database of systematic reviews 9, CD004289, 
doi:10.1002/14651858.CD004289.pub5 (2013). 
43 Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus 
ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): 
a randomised placebo-controlled trial. Lancet 377, 2181-2192, doi:10.1016/S0140-
6736(11)60739-3 (2011). 
44 Vaughan, C. J. & Gotto, A. M., Jr. Update on statins: 2003. Circulation 110, 886-892, 
doi:10.1161/01.CIR.0000139312.10076.BA (2004). 
45 Kotseva, K. et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of 
cardioprotective drug therapies in coronary patients from 22 European countries. 
European journal of cardiovascular prevention and rehabilitation : official journal of the 
European Society of Cardiology, Working Groups on Epidemiology & Prevention and 
Cardiac Rehabilitation and Exercise Physiology 16, 121-137, 
doi:10.1097/HJR.0b013e3283294b1d (2009). 
46 Wei, M. Y., Ito, M. K., Cohen, J. D., Brinton, E. A. & Jacobson, T. A. Predictors of statin 
adherence, switching, and discontinuation in the USAGE survey: Understanding the use 
104 
 
of statins in America and gaps in patient education. Journal of clinical lipidology 7, 472-
483, doi:10.1016/j.jacl.2013.03.001 (2013). 
47 Simpson, R. J., Jr. et al. Treatment pattern changes in high-risk patients newly initiated 
on statin monotherapy in a managed care setting. Journal of clinical lipidology 7, 399-
407, doi:10.1016/j.jacl.2013.06.002 (2013). 
48 Benner, J. S. et al. Long-term persistence in use of statin therapy in elderly patients. 
JAMA : the journal of the American Medical Association 288, 455-461 (2002). 
49 Jackevicius, C. A., Mamdani, M. & Tu, J. V. Adherence with statin therapy in elderly 
patients with and without acute coronary syndromes. JAMA : the journal of the American 
Medical Association 288, 462-467 (2002). 
50 Foody, J. M., Joyce, A. T., Rudolph, A. E., Liu, L. Z. & Benner, J. S. Persistence of 
atorvastatin and simvastatin among patients with and without prior cardiovascular 
diseases: a US managed care study. Current medical research and opinion 24, 1987-
2000, doi:10.1185/03007990802203279 (2008). 
51 Brown, M. T. & Bussell, J. K. Medication adherence: WHO cares? Mayo Clinic 
proceedings. Mayo Clinic 86, 304-314, doi:10.4065/mcp.2010.0575 (2011). 
52 Group, S. C. et al. SLCO1B1 variants and statin-induced myopathy--a genomewide 
study. The New England journal of medicine 359, 789-799, 
doi:10.1056/NEJMoa0801936 (2008). 
53 Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side 
effects. Journal of the American College of Cardiology 54, 1609-1616, 
doi:10.1016/j.jacc.2009.04.053 (2009). 
105 
 
54 Bulbulia, R. et al. Effects on 11-year mortality and morbidity of lowering LDL 
cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a 
randomised controlled trial. Lancet 378, 2013-2020, doi:10.1016/S0140-6736(11)61125-
2 (2011). 
55 Wilke, R. A. et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC 
Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther 92, 
112-117 (2012). 
56 Sathasivam, S. Statin induced myotoxicity. European journal of internal medicine 23, 
317-324, doi:10.1016/j.ejim.2012.01.004 (2012). 
57 Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L. & Hegele, R. A. Genetic determinants of 
statin intolerance. Lipids in health and disease 6, 7, doi:10.1186/1476-511X-6-7 (2007). 
58 Marcoff, L. & Thompson, P. D. The role of coenzyme Q10 in statin-associated 
myopathy: a systematic review. Journal of the American College of Cardiology 49, 2231-
2237, doi:10.1016/j.jacc.2007.02.049 (2007). 
59 Ruano, G. et al. Mechanisms of statin-induced myalgia assessed by physiogenomic 
associations. Atherosclerosis 218, 451-456, doi:10.1016/j.atherosclerosis.2011.07.007 
(2011). 
60 Mangravite, L. M. et al. A statin-dependent QTL for GATM expression is associated 
with statin-induced myopathy. Nature 502, 377-380, doi:10.1038/nature12508 (2013). 
61 Choe, C. U. et al. L-arginine:glycine amidinotransferase deficiency protects from 
metabolic syndrome. Human molecular genetics 22, 110-123, doi:10.1093/hmg/dds407 
(2013). 
106 
 
62 Ide, T. et al. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive 
response to nutrient stress. Molecular cell 36, 379-392, doi:10.1016/j.molcel.2009.09.031 
(2009). 
63 Ferrari, M. et al. Association between statin-induced creatine kinase elevation and 
genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. European journal of clinical 
pharmacology 70, 539-547, doi:10.1007/s00228-014-1661-6 (2014). 
64 Fiegenbaum, M. et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 
genes in lipid-lowering efficacy and safety of simvastatin treatment. Clinical 
pharmacology and therapeutics 78, 551-558, doi:10.1016/j.clpt.2005.08.003 (2005). 
65 Keskitalo, J. E. et al. ABCG2 polymorphism markedly affects the pharmacokinetics of 
atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics 86, 197-203, 
doi:10.1038/clpt.2009.79 (2009). 
66 Frudakis, T. N. et al. CYP2D6*4 polymorphism is associated with statin-induced muscle 
effects. Pharmacogenetics and genomics 17, 695-707, 
doi:10.1097/FPC.0b013e328012d0a9 (2007). 
67 Wilke, R. A., Moore, J. H. & Burmester, J. K. Relative impact of CYP3A genotype and 
concomitant medication on the severity of atorvastatin-induced muscle damage. 
Pharmacogenetics and genomics 15, 415-421 (2005). 
68 Needham, M. & Mastaglia, F. L. Statin myotoxicity: a review of genetic susceptibility 
factors. Neuromuscular disorders : NMD 24, 4-15, doi:10.1016/j.nmd.2013.09.011 
(2014). 
107 
 
69 Marciante, K. D. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. 
Pharmacogenetics and genomics 21, 280-288, doi:10.1097/FPC.0b013e328343dd7d 
(2011). 
70 Ruano, G. et al. Physiogenomic association of statin-related myalgia to serotonin 
receptors. Muscle & nerve 36, 329-335, doi:10.1002/mus.20871 (2007). 
71 Ruano, G. et al. Physiogenomic analysis links serum creatine kinase activities during 
statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6, 865-872, 
doi:10.2217/14622416.6.8.865 (2005). 
72 Thompson, P. D., Clarkson, P. & Karas, R. H. Statin-associated myopathy. JAMA 289, 
1681-1690, doi:10.1001/jama.289.13.1681 (2003). 
73 Vale, N. et al. Statins for acute coronary syndrome. The Cochrane database of systematic 
reviews, CD006870, doi:10.1002/14651858.CD006870.pub2 (2011). 
74 Cziraky, M. J. et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering 
drugs in a real-world clinical setting. Journal of clinical lipidology 7, 102-108, 
doi:10.1016/j.jacl.2012.06.006 (2013). 
75 Keating, A. J., Campbell, K. B. & Guyton, J. R. Intermittent nondaily dosing strategies in 
patients with previous statin-induced myopathy. The Annals of pharmacotherapy 47, 398-
404, doi:10.1345/aph.1R509 (2013). 
76 Austin, P. C. & Mamdani, M. M. Impact of the pravastatin or atorvastatin evaluation and 
infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis 
with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin 
therapy in Ontario, Canada. Circulation 112, 1296-1300, 
doi:10.1161/CIRCULATIONAHA.104.531582 (2005). 
108 
 
77 Keidar, S. & Gamliel-Lazarovich, A. Viewpoint: personalizing statin therapy. Rambam 
Maimonides medical journal 4, e0008, doi:10.5041/RMMJ.10108 (2013). 
78 Zhou, S. F. et al. Clinical pharmacogenetics and potential application in personalized 
medicine. Current drug metabolism 9, 738-784 (2008). 
79 Kraft, P., Zeggini, E. & Ioannidis, J. P. Replication in genome-wide association studies. 
Statistical science : a review journal of the Institute of Mathematical Statistics 24, 561-
573, doi:10.1214/09-STS290 (2009). 
80 Ioannidis, J. P. Why most published research findings are false. PLoS medicine 2, e124, 
doi:10.1371/journal.pmed.0020124 (2005). 
81 Wacholder, S., Chanock, S., Garcia-Closas, M., El Ghormli, L. & Rothman, N. Assessing 
the probability that a positive report is false: an approach for molecular epidemiology 
studies. Journal of the National Cancer Institute 96, 434-442 (2004). 
82 Risch, N. J. Searching for genetic determinants in the new millennium. Nature 405, 847-
856, doi:10.1038/35015718 (2000). 
83 Ioannidis, J. P., Thomas, G. & Daly, M. J. Validating, augmenting and refining genome-
wide association signals. Nature reviews. Genetics 10, 318-329, doi:10.1038/nrg2544 
(2009). 
84 Trikalinos, T. A., Ntzani, E. E., Contopoulos-Ioannidis, D. G. & Ioannidis, J. P. 
Establishment of genetic associations for complex diseases is independent of early study 
findings. European journal of human genetics : EJHG 12, 762-769, 
doi:10.1038/sj.ejhg.5201227 (2004). 
85 Bitzur, R., Cohen, H., Kamari, Y. & Harats, D. Intolerance to statins: mechanisms and 
management. Diabetes care 36 Suppl 2, S325-330, doi:10.2337/dcS13-2038 (2013). 
109 
 
86 Dumitrescu, L. et al. Assessing the accuracy of observer-reported ancestry in a 
biorepository linked to electronic medical records. Genetics in medicine : official journal 
of the American College of Medical Genetics 12, 648-650, 
doi:10.1097/GIM.0b013e3181efe2df (2010). 
87 Burnett, M. S. et al. Reliability of self-reported ancestry among siblings: implications for 
genetic association studies. American journal of epidemiology 163, 486-492, 
doi:10.1093/aje/kwj057 (2006). 
88 Lee, S., Epstein, M. P., Duncan, R. & Lin, X. Sparse principal component analysis for 
identifying ancestry-informative markers in genome-wide association studies. Genetic 
epidemiology 36, 293-302, doi:10.1002/gepi.21621 (2012). 
89 Turner, S. et al. Quality control procedures for genome-wide association studies. Curr 
Protoc Hum Genet Chapter 1, Unit1 19, doi:10.1002/0471142905.hg0119s68 (2011). 
90 Pearson, T. A. & Manolio, T. A. How to interpret a genome-wide association study. 
JAMA : the journal of the American Medical Association 299, 1335-1344, 
doi:10.1001/jama.299.11.1335 (2008). 
91 Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. Annual review of 
genomics and human genetics 10, 387-406, 
doi:10.1146/annurev.genom.9.081307.164242 (2009). 
92 Pirinen, M., Donnelly, P. & Spencer, C. C. Including known covariates can reduce power 
to detect genetic effects in case-control studies. Nature genetics 44, 848-851, 
doi:10.1038/ng.2346 (2012). 
110 
 
93 Li, B. & Leal, S. M. Methods for detecting associations with rare variants for common 
diseases: application to analysis of sequence data. American journal of human genetics 
83, 311-321, doi:10.1016/j.ajhg.2008.06.024 (2008). 
94 Wu, M. C. et al. Rare-variant association testing for sequencing data with the sequence 
kernel association test. Am J Hum Genet 89, 82-93, doi:S0002-9297(11)00222-9 [pii] 
10.1016/j.ajhg.2011.05.029 (2011). 
95 Doring, F. et al. Single nucleotide polymorphisms in the myostatin (MSTN) and muscle 
creatine kinase (CKM) genes are not associated with elite endurance performance. 
Scandinavian journal of medicine & science in sports 21, 841-845, doi:10.1111/j.1600-
0838.2010.01131.x (2011). 
96 Wu, Q. Y. et al. Disrupting of E79 and K138 interaction is responsible for human muscle 
creatine kinase deficiency diseases. International journal of biological macromolecules 
54, 216-224, doi:10.1016/j.ijbiomac.2012.12.034 (2013). 
97 Borges, L., Hsu, M. L., Fanger, N., Kubin, M. & Cosman, D. A family of human 
lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J 
Immunol 159, 5192-5196 (1997). 
98 Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E. & Zhang, B. PhosphoSite: 
A bioinformatics resource dedicated to physiological protein phosphorylation. 
Proteomics 4, 1551-1561, doi:10.1002/pmic.200300772 (2004). 
99 Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28, 
1248-1250, doi:10.1038/nbt1210-1248 (2010). 
111 
 
100 Wang, M. et al. PaxDb, a database of protein abundance averages across all three 
domains of life. Mol Cell Proteomics 11, 492-500, doi:10.1074/mcp.O111.014704 
(2012). 
101 http://www.ncbi.nlm.nih.gov/geoprofiles/81912982, 
<http://www.ncbi.nlm.nih.gov/geoprofiles/81912982> ( 
102 Warren, G. L. et al. CK-MM autoantibodies: prevalence, immune complexes, and effect 
on CK clearance. Muscle Nerve 34, 335-346, doi:10.1002/mus.20594 (2006). 
103 Ebbeling, C. B. & Clarkson, P. M. Muscle adaptation prior to recovery following 
eccentric exercise. European journal of applied physiology and occupational physiology 
60, 26-31 (1990). 
104 Hyatt, J. P. & Clarkson, P. M. Creatine kinase release and clearance using MM variants 
following repeated bouts of eccentric exercise. Medicine and science in sports and 
exercise 30, 1059-1065 (1998). 
105 Delanghe, J., De Scheerder, I., De Buyzere, M., Algoed, L. & Robbrecht, J. Macro CK 
type 1 as a marker for autoimmunity in coronary heart disease. Atherosclerosis 60, 215-
219 (1986). 
106 Dhanoa, B. S., Cogliati, T., Satish, A. G., Bruford, E. A. & Friedman, J. S. Update on the 
Kelch-like (KLHL) gene family. Human genomics 7, 13, doi:10.1186/1479-7364-7-13 
(2013). 
107 Liu, L. et al. Analysis of rare, exonic variation amongst subjects with autism spectrum 
disorders and population controls. PLoS genetics 9, e1003443, 
doi:10.1371/journal.pgen.1003443 (2013). 
 
